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Introduction 
The infectious disease situation differed from that of 
previous years, both at home and abroad. The excep-
tionally long influenza season affecting a large num-
ber of people in Finland, the vast numbers of asylum 
seekers arriving in Europe, and the Zika virus – 
transmitted by mosquitoes and spreading in Brazil – 
posed new challenges for the prevention of com-
municable diseases. 
The dominant virus of the exceptionally long 
2014‒2015 influenza season was an A(H3N2) sub-
type, infecting the people over 75 years in particular. 
A record number of cases caused by influenza virus 
B were reported and –  simultaneously with influen-
za A – cases abounded throughout the season.  
In March–May, an epidemic caused by the bacte-
rium Salmonella Enteritidis affected almost 100 
tourists who had visited Latvia. The epidemic was 
related to junior ice hockey tournaments organised 
in Riga. It is likely that cases occurred even among 
ice hockey players in Sweden and Norway. The 
European Centre for Disease Prevention and Control 
(ECDC) coordinated the investigation of the epi-
demic. The cause for the increasing number of cam-
pylobacter infections in 2014 and 2015 remains 
unknown. More information on the country of origin 
and sources of campylobacter infections would be 
necessary in order to target prevention measures. 
Yet another epidemic was linked to the consumption 
of unprocessed milk. In Raseborg, 19 people con-
tracted Campylobacter jejuni gastroenteritis, which 
was accompanied by a fever. Since up to 60% per 
cent of rotavirus infections were diagnosed in the 
over 5 age group, it seems that the vaccine protects 
younger children fairly well.  
The increasing number of Hepatitis A infections 
diagnosed within a three-year period is linked to 
extensive international food-borne epidemics. The 
number of sexually transmitted diseases has re-
mained unchanged, except for syphilis, which has 
increased in the last two years. In the last ten years, 
the number of HIV cases has remained almost un-
changed and the risk of sexually transmitted HIV 
infections has almost been eliminated, owing to 
modern treatment.  
Thankfully, the number of MRSA infections was 
slightly lower than in the previous year, although a 
previously rare strain of MRSA CC398, linked to 
production animals, was detected in 41 individuals 
in Finland. The number of CPE findings doubled 
over 2014. Approximately one half of CPE infec-
tions had been acquired abroad. Increasing antimi-
crobial resistance poses one of the most serious 
threats to modern medicine.  
The percentage of tuberculosis cases among foreign 
nationals increased by one fifth over the previous 
year, being as high as 39% in 2015. The growing 
numbers of asylum seekers were probably one of the 
contributing factors to this trend. The number of 
drug-resistant Mycobacterium tuberculosis strains 
has also increased slightly in recent years. 
There was a continuous increase in bacterial findings 
in adults' blood culture samples, particularly in pa-
tients aged 65 or over. Escherichia coli was the most 
common finding both in the working age population 
and in patients aged 65 and older. Other common 
findings include Staphylococcus aureus, a signifi-
cant percentage of which is known to consist of 
treatment-related infections. 
The incidence of serotypes not included in the 
pneumococcal conjugate vaccine increased; in pa-
tients aged 65 or older, 80% of cases were caused by 
serotypes not included in the vaccine. The ageing of 
the population and possible changes in disease diag-
nostics and the prevalence of the risk factors of 
pneumococcal disease may be contributing to this 
increase. Record numbers of borrelia and TBE infec-
tions, transmitted by ticks, were identified, the latter 
mainly occurring in known risk areas. Ticks may be 
becoming more widespread due to global warming 
and potential new areas of infection include Porkka-
la, Oulu, Ilomantsi, Muurame, the Rauma archipela-
go and Vierumäki. 
The reform of the Communicable Diseases Act pro-
gressed to the committee reading stage. Unfortunate-
ly – and unexpectedly at this stage – a small group 
of actors began to demand restrictions to the authori-
sations specified in the Act for implementing 
measures essential to the prevention of infections, 
including for persons without right of abode, contra-
ry to the stand taken by the majority of infectious 
disease experts, the National Institute for Health and 
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Welfare THL, and almost the entire working group 
when preparing the legal reform. If realised, this 
change would considerably undermine the precondi-
tions for preventing infectious diseases and possibly 
result in Finland being in breach of its international 
obligations. 
International situation 
The previous year, 2014, was characterised by the 
international public health emergency caused by the 
Ebola epidemic in West Africa. During 2015, how-
ever, an extensive international aid operation man-
aged to gain control of the situation and the number 
of cases fell to almost zero in Guinea, Sierra Leone 
and Liberia. In response, the WHO declared an end 
to the Ebola-related public health emergency in 
2016.  
An extensive, continuously spreading epidemic 
caused by the Zika virus, which is transmitted by 
mosquitoes, was detected in South and Central 
America in 2015. An infection contracted during 
pregnancy seems to cause congenital neurological 
disorders, including microcephaly, in the foetus. An 
increased risk of Guillain-Barré syndrome, with 
symptoms of paralysis, has also been observed in 
infected individuals. Due to the scope of the epidem-
ic and the related birth defects, the WHO declared 
another international public health emergency in 
2016.  It is not possible for the Zika virus to become 
endemic in Finland because the virus-transmitting 
mosquitoes would not survive in our climate. 
Increasing number of asylum seekers 
Migration due to the civil war in Syria and the ex-
panding activities of the terrorist organisation Isis 
was a major development affecting the entire EU 
area in 2015. According to statistics compiled by the 
Finnish Immigration Service, more than 30,000 
asylum seekers arrived in Finland in 2015. The 
number of reception units increased from 28 to 212.  
Although the majority of the asylum seekers are 
healthy young men, there are families with children 
and elderly people whose state of health is not al-
ways good. They may have been exposed to com-
municable diseases in refugee camps or during their 
journey and their immunisation may be deficient due 
to the unstable conditions in the areas they have fled. 
In 2009, the Ministry of Social Affairs and Health 
issued the guidelines “Prevention of infection prob-
lems among refugees and asylum seekers”, on the 
basis of which reception centres governed by the 
Finnish Immigration Service were responsible for 
assessing the risks of infection among immigrants. 
On several occasions during the year, as the recep-
tion of asylum seekers became congested, the Minis-
try of Social Affairs and Health asked the National 
Institute for Health and Welfare (THL) for com-
ments on the prioritisation of the measures described 
in the guidelines, based on international recommen-
dations (by the WHO and ECDC), and the develop-
ment of the situation. Within the collaboration 
agreement between the authorities, concluded by 
THL with the Finnish Immigration Service (MI-
GRI), THL provided MIGRI with the services of the 
Medical Specialists. MIGRI has outsourced its re-
ception centre services, including health care, to 
several actors. In its health care activities, MIGRI 
cooperates with a range of municipal health centres 
and specialised medical care providers.  THL's Med-
ical Specialists allocated a great deal of time to sup-
porting this cooperation. 
The higher number of asylum seekers was clearly 
visible in the number of cases of some infectious 
diseases subject to screening. Outbreaks of chicken-
pox occurred in some reception centres and diphthe-
ria was diagnosed in Finland – for the first time in 
decades – in a young asylum seeker.  The number of 
cases reported to the National Infectious Diseases 
Register (NIDR) without a Finnish identity code 
increased for hepatitis B, syphilis, MRSA, ESBL-
E.coli  and -K.pneumoniae, but not for HIV.  This 
may be partly related to asylum seekers, but no pre-
cise information is available in this respect, because 
the report to the NIDR does not specify whether the 
infected person is an asylum seeker. The guidelines 
of the Ministry of Social Affairs and Health state 
that the purpose of examination for infectious dis-
eases is to protect not only the individual's personal 
health, but also to break chains of infection in order 
to protect everyone residing in Finland.  
Preliminary information indicates that differences in 
interpretation in various parts of the country ham-
pered the implementation of the Ministry of Social 
Affairs and Health guidelines. In two regions, the 
Regional State Administrative Agency issued specif-
ic interpretations of its own on how to apply the 
guidelines which were not in line with the recom-
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mendations of the Association of Finnish Local and 
Regional Authorities and the Ministry of Social 
Affairs and Health. As a consequence, approximate-
ly one third of the asylum seekers were not exam-
ined for all infections as recommended nor they 
receive all recommended vaccinations. In other re-
gions, the examinations and vaccinations were im-
plemented commendably well.  
 
Helsinki, 3 June 2016 
Mika Salminen 
Head of Department 
Department of Infectious Disease Surveillance and 
Control 
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Respiratory infections 
 
 
• The 2014–2015 influenza season was exceptionally long.  
• The dominant virus was an A(H3N2) subtype, infecting the over 75 age group in particular.  
• A record number of cases of influenza B virus were reported and infections  
abounded – simultaneously with influenza A – throughout the season. 
• As before, the influenza vaccination coverage rate remained low.  
• The customary increase in the number of rhinovirus cases was detected in the autumn and 
spring, with more than half of the infections diagnosed in children under the age of 4. 
• As expected, the major RSV winter epidemic of 2014 was followed by a minor epidemic that 
began in January 2015 and continued until July.  
• Of legionellosis infections, the sources of six cases of infection contracted in the home country 
were examined more closely through water samples, and Legionella bacteria were detected in 
two residential buildings. 
 
 
ADENOVIRUS 
In 2015, 1,134 confirmed cases of adenovirus infec-
tion were recorded (2014: 1,004). The largest num-
ber of cases occurred in the under 5 age group (more 
than 500), but numerous cases were also diagnosed 
in the 5 to 9, 15 to 19 and 20 to 24 age groups. In 
February‒April and October‒November 2015, 
slightly more adenovirus infections were reported 
than in the other months (100–128 cases per month). 
At other times of the year, the monthly number of 
adenoviruses was almost the same (66–89 cases per 
month).  
More than 50 types of adenovirus are known. Some 
cause respiratory infections, while others cause gas-
trointestinal, eye or other infections. Adenoviruses 
are common pathogens in infants and small children; 
they rarely occur in adults.  
Laboratories have various test methods for detecting 
adenoviruses in clinical samples. Antigen detection, 
virus cultures and PCR are sensitive and reliable 
methods used in specialised virus laboratories. 
INFLUENZA  
The 2015 winter epidemic season began earlier than 
usual, in December 2014, and continued until the 
end of May. Viruses of the influenza A(H3N2) sub-
type and influenza B emerged as the epidemic dom-
inant virus in the 2014−2015 season. Only individu-
al cases of influenza A(H1N1)pdm09 infections 
were detected during the season. 
Influenza A 
In 2015, 7,701 findings of influenza A were reported 
to the National Infectious Diseases Register, more 
than in the previous year (2014: 6,364). The first 
cases of influenza A infections in the 2014–2015 
season were reported to the National Infectious Dis-
eases Register in October‒November 2014. The 
number of findings increased after mid-November 
2014. National surveillance of influenza virus infec-
tions by the National Institute for Health and Wel-
fare led to the detection of 100 influenza A infec-
tions during the season 2014–2015, of which 97% 
were diagnosed as having been caused by the influ-
enza A(H3N2) virus. Only individual cases of influ-
enza A(H1N1)pdm09 infections were detected dur-
ing the season.  
Data in the National Infectious Diseases Register 
and from the national influenza surveillance of the 
National Institute for Health and Welfare indicate 
that the epidemic season of influenza A peaked in 
February, duringweeks 5 to 9.  The 2014–2015 epi-
demic season proved exceptionally long as the num-
bers of reported influenza A findings remained rela-
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tively high for weeks. The number of cases did not 
decline until in late May to early June. After that, 
only isolated cases of influenza A were detected.  
The number of influenza A cases began to increase 
again after mid-November 2015, which indicated an 
exceptionally early start to the season in 2015–2016. 
Influenza A infections were found in all age groups, 
but unlike the previous year, in the over 75 age 
group in particular (2015: 1,715 cf. 2014: 614). Rea-
sons for the high morbidity in the 75 age group may 
include the abundant incidence of influenza 
A(H3N2) viruses and the antigenic difference be-
tween these viruses and the vaccine virus. The num-
ber of severe infections among the aged is known to 
be higher than in other age groups during influenza 
A(H3N2) virus seasons, which may also be reflected 
in the higher number of findings among older age 
groups.   
Although the national influenza vaccination pro-
gramme has offered a seasonal influenza vaccination 
for medical reasons, free of charge, for children in 
high-risk groups since 1980, and for healthy children 
aged 6 to 35 months since 2007, influenza vaccina-
tion coverage has remained low.   Before the pan-
demic, coverage among children aged 6 to 35 
months was around 40% at best. After the pandemic, 
vaccination coverage among young children was 
around 13% at the lowest point whereas it was 
slightly better, at around 17%, during the 2014–2015 
season.  In 2015, the highest number of influenza A 
cases among the age groups including children and 
young people were reported in the 0 to 4 age group 
(724).  
In spring 2014, after the WHO’s vaccine recom-
mendation for the northern hemisphere for the epi-
demic season 2014–2015, new types of A(H3N2) 
viruses were detected that were antigenically differ-
ent to the vaccine virus. During the summer and 
autumn of 2014, these spread into the southern hem-
isphere and were almost solely responsible for the 
influenza A epidemic in the northern hemisphere in 
the winter of 2015.   
Although the diversity of influenza A(H1N1)pdm09 
viruses has increased since their appearance, the 
epidemic viruses of winter 2015 were antigenically 
similar to the vaccine virus (A/California/07/2009).  
Towards the end of 2015, as the number of influenza 
A cases began to rise again, A(H1N1)pdm09 viruses 
emerged, in turn, as the dominant virus.  
Influenza B 
In 2015, a record number of influenza B cases were 
reported to the National Infectious Diseases Regis-
ter, 5,482 (2014: 778). The previous significant in-
fluenza B epidemic occurred in 2011, with 3,433 
cases of influenza B recorded.  In the epidemic sea-
son 2014–2015, the number of influenza B infec-
tions began to rise early, from the beginning of De-
cember 2014, after which a large number of cases 
was detected throughout the season, simultaneously 
with influenza A infections. After March, the weekly 
number of influenza B findings exceeded that of 
influenza A. Influenza B infections peaked in Febru-
ary–April, in weeks 7–15. As in the case of influen-
za A, the number of cases did not decrease until late 
May to early June.  Influenza B infections were 
diagnosed in all age groups. 
Of the two influenza B virus lineages that have cir-
culated the world in recent seasons, the Yamagata 
lineage has occurred more frequently than the Victo-
ria lineage. The influenza B viruses in circulation 
during the winter of 2015 almost exclusively repre-
sented the Yamagata lineage, with only occasional 
Victoria lineage viruses being found. The Yamagata 
viruses that circulated in Finland belonged to a dif-
ferent group genetically and were antigenically 
somewhat different to the vaccine virus of the same 
lineage (B/Massachusetts/02/2012).  
Vaccine for the epidemic season 2015–
2016 
Based on reports of the influenza A and B epidemic 
viruses circulating the world, the WHO recommend-
ed a change to the vaccination composition in the 
Northern Hemisphere for the epidemic season 2015–
2016 for two virus components. The recommenda-
tion was that the influenza A(H3N2)virus compo-
nent be changed to A/Switzerland/9715293/2013, 
which had a better antigenic correspondence to the 
transformed A(H3N2) viruses circulating as an epi-
demic. The influenza A(H1N1)pdm09 component 
remained unchanged as the A/California/07/2009 
virus. The influenza B virus component was 
changed to B/Phuket/3073/2013, which continued to 
represent viruses of the Yamagata lineage but dif-
THL – Report 15/2016 
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fered antigenically from the influenza B virus com-
ponent previously used in the vaccine. 
Season 2015–2016 
The first cases of influenza A infections were diag-
nosed in November and December 2015, earlier than 
usual as in the previous season. The 2015−2016 
season began early, in December, after which the 
number of influenza A infections increased very 
rapidly. The epidemic began throughout Finland 
almost simultaneously. Influenza A viruses peaked 
in January–February. Unlike previous seasons, more 
than 1,000–2,000 influenza A findings per week 
were reported during the peak weeks 3–6. The num-
ber of influenza B infections began to increase in 
February.  
The influenza A(H1N1)pdm09 viruses, which circu-
lated as the dominant virus of the season, were anti-
genically similar to the vaccine virus.  Influenza B 
viruses detected by mid-March were of the Victoria 
lineage and thereby different to the vaccine virus. 
The occurrence of influenza B viruses of the Victo-
ria lineage increased in Europe during the winter 
2016; it is therefore possible that another epidemic 
wave of influenza B will be experienced later in the 
spring of 2016.  
At the end of February 2016, the WHO issued a new 
vaccine recommendation for the northern hemi-
sphere 2016–2017 epidemic season, based on the 
then current epidemic situation. In the new recom-
mendation, the WHO recommended that the influen-
za A(H1N1)pdm09 component be kept unchanged 
as the A/California/07/2009 virus, but the influenza 
A(H3N2) virus component be changed to A/Hong 
Kong/4801/2014, which is antigenically a better 
match with the A(H3N2) viruses circulating as epi-
demics. Due to the increased occurrence of influenza 
B/Victoria lineage viruses, the WHO recommended 
the inclusion in the vaccine of the 
B/Brisbane/60/2008-virus of the Victoria lineage. In 
addition to the aforementioned viruses, another in-
fluenza B virus, B/Phuket/3073/2013 of the Yama-
gata lineage is recommended for quadrivalent vac-
cines. 
 
 
Figure 1. Cases of influenza A by month, and epidemic virus serotypes, 2006–2015 (no. of cases). 
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Figure 2. Cases of influenza B by month, and epidemic virus serotypes, 2006–2015 (no. of cases). 
PARAINFLUENZA 
Parainfluenza viruses are grouped under one heading 
in the NIDR, even though laboratories usually dif-
ferentiate between parainfluenza viruses 1, 2, 3 and 
4. In 2015, 508 parainfluenza infections were con-
firmed (2014: 556), most of them in the 0 to 4 age 
group (234 cases). Based on the number of cases, no 
separate epidemic peak was detected in 2015, but an 
almost steady number of parainfluenza cases were 
reported throughout the year. The months with the 
highest number of cases (63–67 per month) were 
February and November–December.  
Parainfluenza virus infections are found in patients 
of all age groups. The first parainfluenza infections 
in children can lead to a severe condition that may 
require hospitalisation. In an older child or adult, the 
symptoms of a parainfluenza infection are typically 
much milder.  They often present as an ordinary 
upper respiratory tract infection and do not neces-
sarily require laboratory diagnostics. In special 
groups, however, such as immune deficiency pa-
tients, parainfluenza viruses may cause severe symp-
toms. Almost every year, parainfluenza virus type 3 
causes minor epidemics in the summer and autumn, 
whereas type 1 and 2 viruses do not cause epidemics 
every year.  
RHINOVIRUS 
In 2015, 1,088 confirmed cases of rhinovirus infec-
tion were recorded (2014: 728). In 2015, the typical 
peaks in spring and autumn were detected in the 
number of rhinovirus infections. The numbers were 
highest from April to May (111–120 per month) and 
August to November (109–160 per month), while at 
other times, rhinovirus infections occurred at a 
steady rate every month (38–77 per month). More 
than 50% of these infections were diagnosed in chil-
dren under the age of 4. 
More than 150 types of rhinovirus are known. They 
are the most common cause of mild respiratory in-
fections. Rhinovirus infections are most common in 
young children, but are present in all age groups. 
Since August 2013, rhinoviruses have been included 
in the surveillance of respiratory virus infections 
conducted by the National Institute for Health and 
Welfare (THL), which may partly contribute to the 
increase in the number of cases from 2013 to 2015. 
Laboratories use the PCR test to detect rhinoviruses 
in clinical samples. This test is extremely sensitive 
THL – Report 15/2016 
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and reliable. Specialised virus laboratories are also 
able to culture rhinoviruses. 
RSV 
In 2015, 2,435 cases of RSV confirmed by laborato-
ry tests were reported to the NIDR (2014: 2,369). On 
the basis of long-term surveillance, a major RSV 
epidemic is observed in Finland every other winter, 
often starting in November–December. In addition, a 
minor epidemic occurs between the major ones. As 
expected, the major winter epidemic of 2014 was 
followed by a minor epidemic that began in January 
2015 and continued until July. During the epidemic, 
the number of RSV cases was highest in February to 
March (over 300 cases per month). Individual cases 
of RSV infection were diagnosed during the sum-
mer. In November‒December, the number of RSV 
cases began to increase again, indicating the start of 
another RSV epidemic. 
The majority of RSV cases (almost 80%) were 
found in children aged 0 to 4. Slightly more cases of 
RSV were reported in the over 75 than in other age 
groups. Although RSV infections are present in all 
age groups, cases requiring hospitalisation and la-
boratory diagnostics mainly involve infants and 
small children. 
Reliable quick tests for RSV diagnostics have been 
developed for use at health centres, outpatient clinics 
and hospitals. In hospital conditions, RSV is easily 
transmitted between patients. Quick tests make it 
easier to identify RSV infections and therefore to 
prevent further transmission. Specialised virus la-
boratories increasingly use genetic replication meth-
ods for diagnosing RSV. 
 
 
 
 
Figure 3. Cases of RSV by month, 2006–2015 (no. of cases). 
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ENTEROVIRUS 
In 2015, 119 cases of enterovirus infection were 
reported to the National Infectious Diseases Regis-
ter, considerably less than in 2014 (298) or 2013 
(184). Most cases were found in the autumn, with 
71% being diagnosed in August–December. 
In autumn 2014, severe cases of respiratory infection 
were caused by the type D68 (EV-D68) enterovirus 
in the United States and Canada. Most of the affect-
ed patients were children who required hospitalisa-
tion, particularly among asthma sufferers. EV-D68 
was also identified in a few patients who developed 
polio-like paralysis symptoms after the respiratory 
infection. In Finland, EV-D68 was diagnosed in 
some 20 patients with a respiratory infection in the 
autumn 2014, and in individual patients even in 
2015. No serious cases of illness or neurological 
symptoms appeared. Respiratory infections caused 
by EV-D68 were diagnosed in most European coun-
tries, but no widespread epidemics have been report-
ed.  
Enteroviruses cause not only upper respiratory tract 
infections but conditions such as meningitis, myo-
carditis, hand, foot and mouth disease and other 
types of eczema. PCR methods have increasingly 
replaced traditional virus cultures in enterovirus 
diagnostics. Virus typing is performed on the basis 
of molecular genetics or antibodies.  
WHOOPING COUGH 
In 2015, the number of whooping cough cases re-
ported to the NIDR totalled 165 (3.02/100,000), 
slightly fewer than in 2014 (205; 3.8/100,000). As 
before, the cases were most common in the 0 to 14 
age group, with eleven cases in patients under 12 
months of age and six of them under 3 months of 
age, i.e. under the age of vaccination. The diagnosis 
of patients aged under 12 months was principally 
based on a PCR test (10; 91%) and for most patients 
of other ages, the diagnosis was made on the basis of 
antibody testing (142; 92%).  
Of the children 3 to 23 months of age who contract-
ed whooping cough and whose vaccination data was 
available, four had not been vaccinated while others 
had received 1–3 doses of vaccine containing acellu-
lar component of pertussis. In 2015, of the five Bor-
detella pertussis strains isolated, two did not pro-
duce pertactin. 
As previously, the incidence of whooping cough 
varied considerably by hospital district (0–
15.9/100,000). The incidence was highest in the 
Hospital District of East Savo, while no cases were 
diagnosed in the Hospital Districts of Åland, 
Kainuu, Keski-Pohja and Länsi-Pohja.  
Choosing an optimum vaccination strategy for 
whooping cough is challenging, as the acellular 
vaccines widely used in the western countries are 
incomplete in terms of their efficiency and duration. 
A booster for six-year-olds was added to the national 
vaccination programme in Finland in 2003. In 2005, 
the whole-cell vaccine was replaced with acellular 
combination vaccine containing the Bordetella per-
tussis antigen for children in the age groups covered 
by child care clinics. Until 2007, adolescent vaccina-
tions were given between the ages of 11 and 13. 
Since 2009, the recommendation has been to vac-
cinate adolescents at the age of 14 to 15, i.e. begin-
ning in the 8th grade of comprehensive school. Due 
to this transition, very few of these vaccinations 
were administered between 2009 and 2011. This 
created a temporarily less well protected cohort in 
adolescent age groups. Illness in infancy indicates 
insufficient herd immunity. A whooping cough vac-
cine for conscripts beginning their military service 
was added to the Finnish Defence Forces' vaccina-
tion programme in summer 2012.  
So far, Finland has been spared the extensive 
whooping cough epidemic that generated more than 
40,000 cases in the United States and almost 10,000 
cases in the UK during 2012. In 2012, the year the 
epidemic occurred, on the basis of an extensive 
strain collection in the United States it was discov-
ered that 60% of B. pertussis strains did not produce 
pertactin. Both countries initiated a whooping cough 
vaccination campaign for pregnant women, resulting 
in a significant reduction in the number of whooping 
cough cases in young infants. With respect to Fin-
land’s neighbouring countries, in Sweden the num-
ber of whooping cough cases almost tripled in 2014 
and remained high in 2015 (at some 600 cases). 
Other EU Member States with a high incidence of 
whooping cough (>10/100,000) in 2014 included 
Norway, Denmark, Germany, Belgium, the Nether-
lands, Czech Republic, Slovenia and Slovakia. 
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Figure 4. Cases of whooping cough in children’s and young adults’ age groups, 2006–2015 (no. of cases). 
CHLAMYDIA PNEUMONIAE 
In 2015, 285 cases of Chlamydia pneumoniae were 
reported based on laboratory verification, mainly 
antibody testing. The figure was slightly higher than 
in the previous year. The highest incidence was 
reported in the hospital districts of Vaasa, South 
Ostrobothnia and East Savo, while the number of 
cases was highest in the Helsinki and Uusimaa Hos-
pital District (91). The number of reported infections 
was highest among 5 to 24-year-olds, but cases can 
be found in all age groups.  
LEGIONELLA 
In 2015, 22 cases of legionellosis were reported to 
the National Infectious Diseases Register, of which 
16 were based on the detection of the antigen in 
urine, one on a PCR test of sputum, and five on 
serological methods. Further investigation revealed 
that the clinical presentation was consistent with 
legionellosis in 17 cases, whose chest X-ray re-
vealed changes indicative of pneumonia. The aver-
age age of patients was 61 (variation 50‒74) and 12 
(71%) of them were male.  
Ten (59%) individuals had contracted the infection 
while travelling abroad, seven in Finland. The 
sources of six cases of infection contracted in the 
home country were examined more closely through 
water samples, and Legionella bacteria were detect-
ed in two residential buildings. Two patients had 
been infected in the same premises. L. pneumophila 
bacteria serotype 1 (15,000 cfu/l) and other types of 
legionella (76,000 cfu/l) were detected in the resi-
dence of one of the patients, alongside a high count 
of legionella bacteria in other samples taken on the 
premises (up to a total of 230,180 cfu/l). Cleaning 
measures, including chlorination and raising the 
temperature, succeeded in reducing the count of 
legionella bacteria below the threshold at which 
measures are necessary. On the other premises, 
where one person had been infected, Legionella 
pneumophila bacteria of serotype 1 were found in 
cold household water (230,000 cfu/l, cold water 
temperature 30°C). Legionella bacteria were even 
present in other water samples taken in the same 
block of flats and in the hot water supply.  Monitor-
ing continues on the premises and samples will be 
taken after the completion of cleaning measures. 
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Samples taken at the homes and workplaces of three 
other patients did not reveal the source of infection. 
According to the European guideline for legionella, 
the threshold for measures requiring the cleaning of 
the cold and hot household water supply is >1,000 
cfu/l of legionella. The common factor for both 
premises was that water temperatures did not com-
ply with recommendations. This facilitated the 
growth of legionellas in the water supply systems. 
According to the National Building Code of Finland, 
section D1, the hot water temperature must be 55–
65°C and the recommended maximum temperature 
of cold household water is 20°C.  
Accommodation data relating to all of the patients 
who fell ill abroad was reported to the ELDSNET 
database (European Legionnaires’ Disease Surveil-
lance Network), which collects data on travel-related 
cases of legionellosis. European surveillance indi-
cates that the majority (around 60–70%) of cases are 
of community origin, some 20% are associated with 
travel and fewer than 10% originate in hospitals. In 
Finland, cases of legionellosis are traditionally 
linked with travel. Legionella is therefore often 
overlooked as the potential pathogen in pneumonia 
cases of domestic origin. In 2011‒2013, 77‒100% of 
cases of legionellosis in Finland were travel-linked 
but in 2014, only 20% were, which was slightly 
exceptional. 
MYCOPLASMA PNEUMONIAE 
In 2015,  the total number of Mycoplasma pneu-
moniae cases confirmed in laboratory tests was 
1,671, lower than in the previous years. During the 
previous epidemic in 2012, the number of cases 
exceeded 4,600 and in 2011 the total was over 
7,800.  We seem to be experiencing a period be-
tween epidemics and two or three years remain be-
fore a new winter epidemic occurs. 
The highest number of M. pneumoniae cases are 
diagnosed in the 5 to 19 age group. As in previous 
years, the majority of cases (almost 500) were rec-
orded in the Helsinki and Uusimaa Hospital District. 
The incidence was still highest in the Hospital Dis-
trict of East Savo (70/100,000).  
 
 
Figure 5. Cases of Mycoplasma pneumoniae and Chlamydia pneumoniae by month, 2006–2015 (no. of cases). 
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Gastrointestinal infections 
 
 
• In March–May almost 100 tourists who had visited Latvia contracted an infection caused 
by the Salmonella enteritidis bacterium. The outbreak was detected when three 
individuals were hospitalised due to gastrointestinal symptoms after participating in an 
ice hockey tournament in Riga. 
• In April, 19 people contracted gastroenteritis accompanied by a fever after visiting a 
cowshed. Some  of them had consumed unprocessed milk on the farm. Laboratory tests 
confirmed that the bacterium Campylobacter jejuni was the pathogen. 
• The number of Clostridium difficile cases remained on a par with the last few years, with 
almost half of the patients being 75 or older. With regard to laboratory methods, the 
share of nucleic acid detection rose to 60 per cent. 
• The number of EHEC infections has been rising since 2013. Advances in laboratory diagnostics 
and epidemics are factors underlying the higher number of cases.  
• Once again, frozen berries were the suspected source of an international epidemic of hepatitis A.  
• The number of campylobacter infections has increased in 2014 and 2015, but the reason for this 
remains unknown. More information on the country of origin and sources of infections is 
necessary in order to target prevention measures. 
• As in previous years, the number of norovirus infections was highest in January–May. 
• Of rotavirus infections, almost 60% of cases occur in patients aged 5 and older, whereas the 
percentage of such cases before vaccinations was approximately 10%.  More than one half of 
rotavirus cases in children under 5 years of age occurred in unvaccinated individuals.  
 
 
FOOD- AND WATER-BORNE OUT-
BREAKS 
The National Institute for Health and Welfare sup-
ports municipal outbreak investigation working 
groups focusing on food- and water-borne outbreaks 
and, whenever necessary, coordinates the investiga-
tion of outbreakss e.g. if the outbreak in question is 
exceptionally severe or geographically widespread. 
In 2015, in cooperation with the University of Hel-
sinki, the National Institute for Health and Welfare 
(THL) carried out a customer survey for environ-
mental health care units in order to analyse the 
smoothness of cooperation between the local inves-
tigation working groups and THL. More than half of 
the working groups that responded had contacted 
THL on an annual basis. In addition to reporting 
epidemics, they most often contacted THL in order 
to assess whether further measures and investiga-
tions were necessary. The working groups' experi-
ences of THL's epidemic analysis operations were 
mainly positive, but the respondents hoped that the 
register IT system for food poisoning epidemics 
(RYMY) and the statistical software for analysis of 
epidemics could be made more user-friendly. In 
2015, 52 notifications of suspected cases were en-
tered in the RYMY system (2014: 77). The National 
Institute for Health and Welfare (THL) contacted the 
municipal outbreak investigation working group 
with regard to 19 notifications. Several other gastro-
intestinal infection clusters were investigated as 
well. 
In March–May, almost 100 tourists from different 
parts of Finland, who had visited Latvia, contracted 
an infection caused by the Salmonella enteritidis 
bacterium. The epidemic was detected in Kuopio 
when three individuals having participated in an ice 
hockey tournament in Riga were hospitalised due to 
severe gastrointestinal symptoms. The S. Enteritidis 
strain was more specifically typed in relation to 14 
of the patients. The epidemic was caused by a strain 
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of MLVA type 3-10-6-4-1 and phage type FT 1. The 
questionnaire revealed a certain ice rink as the con-
necting factor and the majority of patients had had at 
least one meal at the ice rink during the weekend of 
the tournament. The National Institute for Health 
and Welfare (THL) informed the European Centre 
for Disease Prevention and Control (ECDC) and the 
World Health Organisation (WHO) about the epi-
demic, while the Finnish Food Safety Authority 
Evira informed the food safety authorities in Latvia.  
The international epidemic investigation coordinated 
by the ECDC has not yet been completed.  
In April, 19 individuals from Kemiönsaari contract-
ed diarrhoea and fever after visiting a cowshed. 
Some of them had consumed unprocessed milk on 
the farm. The C. jejuni strain found in 11 persons 
was typed using the PFGE method, while full ge-
nome sequencing was used in five cases. In addition, 
two C. jejuni strains from the milk filter in the milk-
ing robot, and two from the joint faeces of the cows, 
were typed. A campylobacter strain identical with 
the patients' strains was detected both in the milk 
filter and the faeces sample.  
In July, 45 people contracted an infection caused by 
the Salmonella Newport bacterium in Helsinki, 
probably after consuming chia seed puddings. The 
puddings were prepared, unheated, at the shop which 
was selling them. Salmonella was not detected in the 
food samples analysed in connection with the epi-
demic.  
In September, an estimated 700 people fell ill in 
Nurmijärvi in an epidemic suspected to have been 
caused by household water.  A questionnaire con-
ducted for schoolchildren revealed that the patients  
mainly suffered from short-term diarrhoea and 
stomach cramps. A total of 24 people consulted the 
local health centre, but no pathogens were detected 
in the two samples analysed from patients. The epi-
demic was detected when an E. coli bacterium was 
found in a water sample taken from the tank tower in 
Nurmijärvi as part of the supervision of the quality 
of drinking water supplied to households. Official 
analyses revealed coliform bacteria and E. coli bac-
teria in the samples taken from the Nurmijärvi tank 
tower and the water supply network. Even campylo-
bacter was found in one of the samples from the 
water supply network. People were urged to boil all 
drinking water as it became clear that the household 
water supply had been contaminated, and the distri-
bution of clean water began. It was suspected that 
the contamination was due to the tank tower becom-
ing contaminated. A previous pipe breakage had 
resulted in loss of pressure in the network. As a 
consequence, the water reservoir in the tank tower 
became contaminated through a service hatch, venti-
lation or overflow pipe in the tower and, upon the 
next pipe breakage, all of the contaminated water 
from the tower entered the network. The general 
public was informed about the situation in bulletins 
distributed via public premises in the municipality 
and the online information system for the parents of 
schoolchildren and students, as well as via the mu-
nicipality's website and an emergency warning. The 
contaminated network was cleaned by emptying and 
washing the tank tower, rinsing the networks and 
through protective chlorination (1‒2 mg Cl2/l) of the 
water within the network.  
In November–December 2015, 12 cases of Salmo-
nella Java were found in different parts of Finland. 
The strains found in the patients were divided into 
three types of PFGE, which were separated into two 
groups through full genome sequencing, and no 
common factor was established in interviews.     
When epidemics arise, European countries can pro-
vide and gain information on epidemic investiga-
tions in other countries through the Epidemic Intelli-
gence Information System EPIS, coordinated by the 
European Centre for Disease Prevention and Control 
(ECDC). In 2015, the National Institute for Health 
and Welfare participated in the prevention and ex-
amination of 57 international bacterial gastrointesti-
nal epidemics, by providing up-to-date information 
on the situation in Finland.  
CLOSTRIDIUM DIFFICILE 
In 2015, of the total of 5,821 cases of Clostridium 
difficile reported to the National Infectious Diseases 
Register, either 5,488 (94%) of cases involved a 
toxin-producing strain or PCR was the diagnostic 
method. The number of cases was similar to that of 
recent years. Women accounted for 57%, under 15-
year-olds for 5% and 75-year-olds or older people 
for 48% of cases; 3% concerned under 2-year-olds. 
The four largest clinical microbiology laboratories 
accounted for more than 50% of the findings.  Dif-
ferences in incidence between hospital districts have 
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become slightly smaller, but remain significant 
(58─196/100,000).  
The distinct change in laboratory methods that began 
in 2014 continued. Until 2013, most findings 
(80‒90%) were cultured and less than 5% were nu-
cleic acid detections, but in 2014 only 50% were 
cultures and the share of nucleic acid detections rose 
to 34%. In 2015, the use of nucleic acid detection 
methods almost doubled year-on-year, accounting 
for 60% of the findings, and the proportion of cul-
tures decreased by 15 percentage points to 38% of 
the findings, while the share of antibody findings 
was under 10%. 
In C. difficile diagnostics, the tests should should 
always be performed on diarrhoeal faecal samples 
that take on the shape of the container, the only ex-
ception being patients suffering from paralytic ileus 
or a toxic megacolon. Carriers showing no symp-
toms should not be screened.   
The National Institute for Health and Welfare types 
strains related to suspected epidemics and severe 
individual cases. Of the strains typed in 2015, 65% 
produced not only A and B toxins but also binary 
toxins and had a deletion in the tcdC regulating 
gene. However, ribotype 027 was not involved. In 
addition, a sample of 200 consequent strains from 
the HUS region was typed in 2015. Ribotype 027 
was not found in this sample either, and the majority 
of strains were ordinary toxin-producing strains of 
various ribotypes.  Regardless of the absence of type 
027, the share of strains producing binary toxins was 
18% and 21% of the strains had a deletion in the 
tcdC regulating gene. These represented several 
different ribotypes, most commonly 016, 023, 078 
and 126. The toxine gene profile of ribotype 016 is 
identical with ribotype 027 and in hypervirulence 
screenings, identified as ribotype 027 on a prelimi-
nary basis.  
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Figure 6. Cases of Clostridium difficile by hospital district and by year, 2008–2015 (no. of cases). 
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ENTEROHAEMORRHAGIC  
ESCHERICHIA COLI (EHEC) 
A total of 74 microbiologically confirmed cases 
caused by enterohaemorrhagic Escherichia coli 
(EHEC) were reported to the NIDR (1.4/100,000). 
The incidence was highest in the 0 to 4 age group 
(3/100,000) and 38% (28) of the cases were classi-
fied as being of domestic origin. 
The number of EHEC infections has increased clear-
ly since 2013 (2006‒2012: 8‒31, 2013: 98, 2014: 
64). Changes in the laboratory diagnostics of EHEC, 
including the increasing number of PCR tests, ex-
plain the higher number of infections. Epidemics 
have also influenced the number of cases.  
Since 2014, information on symptoms and exposure 
relating to EHEC infections of domestic origin has 
been collected using an electronic interview form 
completed by municipal officials responsible for 
infectious disease control. The interview data indi-
cates that three patients were diagnosed with hemo-
lytic uremic syndrome (HUS). 
The bacterial culture of 64 EHEC cases sent to a 
laboratory, confirmed using the PCR method. The 
strain of 62 cases of EHEC was received for further 
analysis. Strains of serotype O157:H7 caused a total 
of 20 cases (32%), of which 9 were of domestic 
origin.  
All O157 strains were sorbitol negative. Of the 
strains, 18 were positive for both stx1 and stx2 
genes, while two had the stx2 gene only. The O157 
strains were divided into 5 phage types, the PT 8 
being most common in strains of both domestic and 
foreign origin. 95% of the strains were typed using 
PFGE genotyping. Only two strains had the same 
genotype (1.257), while the other strains analysed 
were individual types. 
There were 42 cases of serogroup Non-O157. Of 
these, 50% were of domestic origin. Of serogroup O, 
the most common were O26 (9 strains), O55 (6), 
O103 (4) and O145 (4). All O145 strains, most of 
the O103- (3/4) and O55 strains (4/6) were of do-
mestic origin, whereas more than one half (5/9) of 
the O26 strains were foreign. 86 % of the strains 
were typed using PFGE genotyping. The domestic 
O55 strains belonged to the same family cluster 
(genotypes O55d and O55h), while the other strains 
analysed were individual genotypes. Thirteen strains 
could not be typed using the traditional serotyping 
method based on agglutination, but their serogroup 
O was analysed through full genome sequencing. 
Of the three HUS cases of domestic origin, two were 
caused by serotype O26:H11 and one by serotype 
O10:H2. All three strains were positive for the stx2 
gene and eae gene and shared the same subtype of 
stx2 gene (stx2a). 
 
Figure 7 EHEC cases by year, 2006–2015 (no. of cases). 
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CAMPYLOBACTER 
Campylobacter is the most common bacterial cause 
of gastrointestinal infections in Finland.  In 2015, 
4,589 findings of campylobacter were reported 
(2014: 4,887). Campylobacter jejuni was by far the 
most common type of campylobacter (4,309), while 
354 cases of C. coli were reported. The type was not 
specified in 154 cases.  
The incidence in the entire population was 
84/100,000. Men accounted for 55 percent of the 
cases, which were most common in the age group 
25–29 (incidence 148/100,000). Incidence was high-
est in the hospital district of Helsinki and Uusimaa 
(121/100,000). Seasonal variation was typical for 
campylobacter as the incidence was highest in July–
August.  
In 55% of the cases, data was lacking on the country 
of acquisition. Of the infections, 14% (632) were of 
domestic origin. Foreign travel was a factor in many 
cases; the most common source being Spain (230), 
followed by Thailand (197) and Turkey (164). 
The number of campylobacter infections has in-
creased in 2014 and 2015 but the reason remains 
unknown. Since a large number of notifications lack 
data on the country of acquisition, it is difficult to 
assess the number of infections of domestic origin. 
More information on the country of origin and 
sources of campylobacter infections would be neces-
sary if prevention measures are to be targeted.     
The bacterial cultures of 21 cases of campylobacter 
were subtyped in THL; of these, 14 strains of  
Campylobacter jejuni  
were linked to the Kemiö epidemic originating in 
unprocessed milk. Five strains of Campylobacter 
coli were analysed due to suspected epidemics, but 
the tests revealed that this was not a question of an 
epidemic caused by an individual strain. 
LISTERIA 
In 2015, a total of 46 systemic infections caused by 
the bacterium Listeria monocytogenes were diag-
nosed (2014: 65). Of these cases, one half were over 
the age of 75 and 57% (26) were women. The lis-
teria cases were spread out across the country. For 
the time being, information on pregnancy is not 
being reported to the National Infectious Diseases 
Register. No cases of listeriosis were diagnosed in a 
newborn baby on the basis of laboratory referrals. 
Upon the introduction of electronic notification of 
infectious diseases by physicians, surveillance data 
for listeriosis will also be specified. 
The L. monocytogenes strain isolated from the pa-
tient’s blood and/or cerebrospinal fluid arrived for 
typing at THL. Of the strains, 37 (82%, 69% in 
2014) were of serotype IIa, determined through 
PCR, 7 of group IVb and of group IIc. 42 of the 
strains were typed using PFGE and they were of 33 
types of PFGE. According to PFGE, clusters of 
more than three cases did not occur. Full genome 
sequencing retroactively confirmed a five person 
cluster that occurred between June and October. In 
the PFGE analysis conducted on three out of five 
strains, the strains were of two PFGE types (Asc2-
Apa4 and Asc5-Apa2).  
Up-to-date PFGE profiles on L. monocytogenes 
strains were sent to the international database coor-
dinated by the ECDC. In 2015, three small-scale 
international clusters were found that included the 
PFGE profiles of Finnish strains.   
SALMONELLA 
In 2015, a total of 1,656 salmonella cases were re-
ported (2014: 1,622), of which 55% had been de-
tected in women. The annual incidence in the entire 
country was 30/100,000 population. The incidence 
was highest in the Hospital District of Central Os-
trobothnia (40/100,000) and lowest in the Åland 
(7/100,000). The highest number of infections was 
reported in the 20 to 24 age group. 
The S. Typhi bacterium, which causes typhoid fever, 
was identified in one person, who had travelled to 
Bangladesh. Six cases of S. Paratyphi, which causes 
paratyphoid fever, were found, four of Paratyphi A 
and two of Paratyphi B, five of which were related 
to travel abroad. 
The bacterial strain of a total of 1,583 cases of sal-
monella was sent to the National Institute for Health 
and Welfare. The number of strains was slightly 
higher than in the previous year (1,428). Of them, 
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1,238 (78%) were of foreign and 311 (20%) of do-
mestic origin. In 32 (2%) cases, the origin of the 
salmonella infection remained unclear. 
Domestic salmonella infections were caused by 54 
different serotypes. The three most common, includ-
ing Typhimurium (79 cases), Enteritidis (59) and 
group B (30), caused 54% of infections. Most (80% 
cf. 2014: 70%) cases were still susceptible to all 12 
antimicrobials tested, and the proportion of multire-
sistant strains decreased markedly from the previous 
years' level (2015: 12%; 2014: 20%; 2013: 21%). 
Of the domestic strains of Typhimurium, only 6% 
were multiresistant (2014: 17%). Typhimurium 
strains were divided into 11 different phage types. 
The percentage (29%) of the traditional endemic PT 
1 phage type was on a par with the previous year 
(2014: 32%). All PT strains were susceptible to 
antimicrobials. 
The usual number of cases were caused by the do-
mestic Enteritidis serotype (59, in 2014:). 49). Most 
strains were susceptible to all of the antimicrobials 
tested (80%). Enteritidis strains were divided into 15 
different phage types, the most common, as in the 
previous year, being PT 8 (34%, 2014: 24%). The 
number of domestic group B cases (30) has stabi-
lised after the increase of a few years ago. Most of 
the strains in group B were so-called monophasic S. 
Typhimurium strains (25 cases). All monophasic 
Typhimurium strains isolated from infections of 
domestic origin were multiresistant; most commonly 
to ampicillin, streptomycin, sulfonamide and tetra-
cycline. 
This resistance gives us reason to suspect that the 
monophasic Typhimurium strains are actually of 
foreign origin, e.g. secondary cases related to some-
one who returned from abroad or originating in an 
imported food product. Multiresistant monophasic 
Typhimurium strains are not known to occur in do-
mestic farm animals. The most common monophasic 
phage type has varied in previous years (PT 120, PT 
195, PT 193), but in 2015, PT 7A (7/25) was most 
common. 
Of foreign strains, 19% were serotyped. Selection 
focussed on strains originating in the 
WHO/European countries (53 countries in Europe 
and close by). The most common serotypes were the 
same as in the previous year; Enteritidis, group B, 
Typhimurium and Stanley. The leading countries of 
acquisition for cases of foreign origin were Thailand 
(23%), Turkey (16%), Latvia (5%), Spain (5%) and 
Indonesia (3%). The number of strains from the 
WHO/European countries increased by almost one 
quarter year-on-year (577 cf. 402), while the number 
of strains originating outside the WHO/European 
countries was on a par with the previous year (661 
cf. 691). 
Table 1. The most common serotypes of salmonella cases of domestic origin, 2007–2015 (excluding S. Typhi 
and S. Paratyphi) (no. of cases). 
 
2007 2008 2009 2010 2011 2012 2013 2014 2015 
Domestically acquired infections (Source: National Institute for Health and Welfare, Bacterial Infections Unit) 
Salmonella Typhimurium 156 85 140 132 94 98 94 92 79 
Salmonella Enteritidis 62 48 51 44 47 83 46 49 59 
Salmonella group B 11 5 7 8 40 35 38 32 30 
Salmonella Newport 28 71 9 8 6 7 11 9 27 
Salmonella Java 0 0 0 0 2 0 2 5 13 
Salmonella Infantis 3 7 2 9 10 36 12 9 10 
Salmonella Saintpaul 2 6 2 2 0 5 4 4 6 
Salmonella Stanley 11 8 6 7 1 3 1 6 6 
Salmonella Oranienburg 0 7 2 2 43 2 4 2 5 
Salmonella Panama 0 1 0 0 0 0 3 3 5 
Salmonella Agona 40 15 2 2 11 33 12 8 4 
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Figure 8. Salmonella and campylobacter cases by month, 2006–2015 (no. of cases). 
 
SHIGELLA 
In 2015, the incidence of shigellosis was 
1.6/100,000. The total number of cases reported was 
92 (in 2014: 89). Of these, 52 were in women and 
the median age was 35 years (variation 1–73). The 
majority of cases (74) were detected in individuals 
aged 20–59, and 74% (68) were reported in the Hel-
sinki and Uusimaa Hospital District. Eleven hospital 
districts had no diagnosed cases. The lack of find-
ings in so many hospital districts gives reason to 
suspect problems in the primary diagnostics of shi-
gella, which is known to be challenging.  
The shigella strain of 85 persons was sent to the 
National Institute for Health and Welfare laboratory. 
Of the total, 67 infections (79%) were reported as 
having been acquired abroad, 16 in Finland and, in 
two cases, the country of acquisition was not report-
ed. As in the previous year, the most common coun-
tries of origin were India (11 cases) and Thailand 
(6). A total of 52 strains (61%) were typed, includ-
ing all infections of domestic origin and a sample of 
the foreign ones. The prevailing shigella species 
were Shigella sonnei (31 cases) and Shigella flexneri 
(17 cases). Antimicrobial susceptibility testing was 
performed on 53 strains, of which 43 (81%) were 
multiresistant (resistant to at least three of the 12 
antimicrobialstested). Antimicrobial susceptibility 
testing was performed on nine of the domestic 
strains, of which 7 were multiresistant.     
YERSINIA 
Yersinia findings are reported to the National Infec-
tious Diseases Register under the Communicable 
Diseases Decree, which does not, however, require 
that Yersinia strains are sent to the National Institute 
for Health and Welfare THL. Since 2014, THL has 
only typed Yersinia strains related to special condi-
tions such as epidemics or serious infections.  
Yersinia enterocolitica 
In 2015, 560 cases of Yersinia enterocolitica were 
reported to the NIDR (2014: 499). The incidence 
rate in the entire country was 10/100,000 and was 
highest in the 25–29  age group (15/100,000). Re-
gional variation was remarkable: the incidence was 
highest in the Helsinki and Uusimaa (17/100,000), 
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Central Ostrobothnia (13/100,000) and Kainuu 
(13/100,000) hospital districts. Only one case of Y. 
enterocolitica was diagnosed in the Åland Islands 
and East Savo hospital districts in 2015. 
Y. enterocolitica is most commonly identified from a 
stool culture. In 2015, the number of cases con-
firmed by culture totalled 519, while 44 cases were 
identified by antibody findings in serum. Nine cases 
were identified by two different methods (PCR and 
culture or culture and antibody typing). In the Hel-
sinki and Uusimaa hospital district, the typing result 
for Y. enterocolitica was given in 74% (198/267) of 
cases. Of the cases typed, 71% (140/198) were of 
biotype BT1A, 22% of bio/serotype BT4/O:3 and 
7% BT2/O:9. BT 1A is a heterogenous group of 
strains that lack the pYV virulence plasmid typical 
of pathogenic yersinias. However, some BT 1A 
strains may have other properties affecting their 
pathogenic capabilities. The typing result of approx-
imately one fifth (56/294) of cases was reported by 
other hospital districts. Of the cases typed, 48% 
were of biotype BT1A or strains whose virulence 
plasmid was not identified. Three strains of Y. enter-
ocolitica isolated from blood were of serotype O:3. 
Yersinia pseudotuberculosis 
The number of Yersinia pseudotuberculosis cases 
(16) in 2015 was considerably lower than in the 
previous year (74), when an epidemic related to 
unprocessed milk was diagnosed. In 2015, the inci-
dence for the entire country was 0.3/100,000 inhab-
itants. Of the cases, 11 were confirmed by culture 
and 5 by antibodies. 
NOROVIRUS 
In 2015, 2,164 cases of norovirus were reported to 
the National Infectious Diseases Register. Notifica-
tions were submitted by all hospital districts and, as 
in previous years, the majority in January‒May 
(1,802, 83%). Cases occurred in all age groups, but 
more than one half of them in persons over 75 years 
old. The percentage of women was 57%.  
Norovirus is one of the most common causes of 
food- and water-borne epidemics. In 2015, 15/52 
suspected epidemics in which the suspected patho-
gen was norovirus were reported to RYMY, the 
national register IT system of THL and Evira. 
Since late 2014, the most common type of norovirus 
typed by the THL is GII.e, found in almost all of the 
samples analysed in early 2015. The genotype GII.e 
has developed through mutations from the globally 
highly common genotype GII.4, detected in Finland 
for the first time in 2008. Other types of norovirus 
found in 2015 included GI.7, GI.2, GI.3, GI.5, GI.b 
and GII.17, confirmed as the pathogen in an epidem-
ic diagnosed in Helsinki at the end of 2015. A no-
rovirus of the genotype GII.17 caused epidemics in 
China in winter 2014‒2015 and after that, several in 
Russia (22 epidemics/2015), France (4), Germany 
(1) and the Netherlands (1).   In Finland, noroviruses 
GI.7 (2, Tampere) and GII.e (10, Kuopio), were also 
confirmed as having caused epidemics. 
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Figure 9. Cases of norovirus infection by month, 2006–2015 (no. of cases). 
 
ROTAVIRUS 
In 2015, 251 cases of rotavirus were reported to the 
National Infectious Diseases Register. The number 
of cases has remained below 500 since the rotavirus 
vaccine was introduced to the national vaccination 
programme in 2009. Comprehensive rotavirus vac-
cinations for young children have clearly lowered 
the incidence of rotavirus infections in under 5-year-
olds (2015: 36/100,000) in comparison with the 
average incidence (460/100,000) in this age group 
prior to the vaccination programme. A continuously 
increasing percentage of cases occur in patients aged 
5 and older (2015: 57%), whereas the percentage of 
such cases before the vaccinations was approximate-
ly 10%. More than one half of rotavirus cases in 
children under 5 years of age occurred in unvac-
cinated individuals.  
The National Institute for Health and Welfare main-
tains the microbial strain collection of rotaviruses in 
accordance with the Communicable Diseases Act 
and Decree and is monitoring whether the virus 
strains that have reduced due to vaccination are be-
ing replaced by other virus strains. Rotavirus posi-
tive findings sent by clinical laboratories to the Na-
tional Institute for Health and Welfare are typed on 
the basis of molecular genetics by the University of 
Tampere Vaccine Research Center. In 2015, the 
most common type of rotavirus that caused out-
breaks of cases was G2P[4]. The same genotype also 
prevailed in Austria and Belgium, where rotavirus 
vaccination coverage is as high as in Finland. After 
G2P[4], the next most common types of rotavirus in 
Finland were G1P[8], G9P[8], G3P[8] and G12P[8]. 
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Figure 10. Rotavirus cases by age group in children aged 0 to 4, 2006–2015 (no. of cases). 
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Hepatitis 
 
 
• The number of hepatitis A infections of domestic origin was relatively high for the third year 
running, due to extensive international food-borne epidemics. 
• Only six cases of acute hepatitis B infection were reported to the National Infectious Diseases 
Register. The decrease in the number of infections is mainly due to higher vaccination coverage. 
• A significantly higher number of chronic hepatitis B infections was reported than in the previous 
year. The growth in the number of infections occurred among foreigners, who accounted for 90% 
of all cases.   
• The majority of patients infected with hepatitis C in Finland were intravenous drug users. A very 
high percentage, around 75%, of intravenous drug users have been found to have hepatitis C 
antibodies 
. 
 
 
HEPATITIS A 
In 2015, 45 cases of hepatitis A were reported 
(0.8/100,000) (2014: 27). The median age in these 
cases was 25 years (variation 1–66). Men accounted 
for 53% (24) of the cases, the highest number of 
them being reported in the Helsinki and Uusimaa 
Hospital District (28). Of these infections, 19 (42%) 
were contracted in Finland. The percentage of do-
mestic infections was relatively high for the third 
consecutive year. The extensive international food-
borne epidemics of recent years explain the situa-
tion.  
HEPATITIS B 
In 2015, only six (0.1/100,000) acute cases of hepa-
titis B, i.e. ones that tested positive for IgM antibod-
ies, were reported to the National Infectious Diseas-
es Register, which is the lowest annual number so 
far. Four of the infected patients were of Finnish 
origin, two foreign. The mode of transmission was 
reported in one case only, being sexual contact. The 
country of acquisition was reported in four cases, in 
two as Finland and in the other two as a foreign 
country. 
In the last ten years, the reported annual average 
number of acute hepatitis B infections is 20 whereas 
in the record year, 1998, almost 180 infections were 
reported. This decrease is mainly due to higher vac-
cination coverage. Vaccination of risk groups began 
in Finland in the 1990s. In addition, the vaccine has 
been popular, particularly among travellers. Moreo-
ver, needle and syringe exchange has probably pre-
vented infections among users of intravenous drugs.  
A significantly higher number of chronic hepatitis B 
infections, 391 (7.2/100,000), was reported than in 
the previous year. The growth in the number of in-
fections occurred among foreigners, who accounted 
for 90% of all cases.  Of these infections, 63% were 
reported in men and 37% in women The mode of 
transmission was reported in only 10% of cases, 
with perinatal infections and infections due to sexual 
contact being most common. 163 infections (2014: 
42) were diagnosed in individuals who do not have a 
Finnish identity number. Growth in this group is 
partially explained by the fact that asylum seekers 
arriving in Finland have been actively screened for 
hepatitis B. 
The number of cases of chronic hepatitis B has de-
creased since it peaked at over 600 in 1996. The 
reason is the sharp decline in the number of cases 
reported in Finns. No such decline has taken place 
among infections in foreigners. 
HEPATITIS C 
In 2015, 1,165 (21/100,000) new cases of hepatitis C 
were reported to the National Infectious Diseases 
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Register, on a par with the previous year. The high-
est number of infections (33%) was reported in the 
Hospital District of Helsinki and Uusimaa, while the 
incidence rates were highest in the hospital districts 
of Länsi-Pohja (44/100,000), the Åland  
(38/100,000) and South Karelia (35/100,000) and 
the lowest in Central Ostrobothnia (9/100,000), 
South Ostrobothnia (11/100,000) and Central Fin-
land (14/100,000). 
Men accounted for 66% of the cases, which were 
most frequent in the age group 20–39, accounting 
for 67% of the cases. The incidence was highest 
(70/100,000) in the age group 20 to 24.  
The majority of infections (81%) were diagnosed in 
individuals of Finnish origin. The country of acqui-
sition was known in 58% of the cases. Of these, the 
majority (86%) were infections contracted in Fin-
land. 
Intravenous drug use was the most common method 
of infection (49%). Information on the mode of 
transmission was lacking in 40% of cases. Sexual 
contact was given as the mode of transmission in six 
per cent. Of these cases, one half was diagnosed in 
women, the other in men. Only one infection was 
reported as being acquired through sexual contact 
between men. 
The majority of hepatitis C infections were reported 
without an identity number in 1995‒1997. The high 
figures for hepatitis C in 1996–2000 (1,800 cases on 
average per year) may have been partially due to 
cases without identity numbers being registered 
several times, and the probable registration for those 
years of most cases initially diagnosed before sur-
veillance began. Since 2003, the annual number of 
cases has varied between 1,100 and 1,200, the low-
est figure being recorded in 2009 (1,036).   
In all, almost 29,000 cases of hepatitis C have been 
reported to the National Infectious Diseases Register 
in 1995–2015.  However, the total number of those 
infected and carriers is unknown because the preva-
lence rate of hepatitis C has not been studied at pop-
ulation level in Finland.  
The majority of infected patients in Finland are in-
travenous drug users. A very high percentage, 
around 75%, of intravenous drug users have been 
found to have hepatitis C antibodies. Because of 
this, it is difficult to reduce the number of infections 
further in this group by means of needle and syringe 
exchange programmes alone. The number of carriers 
is growing because the number of new infections is 
clearly higher than the number of cases treated. 
 
Table 2. All cases of hepatitis C according to physicians’ reports, by mode of transmission, 2006–2015 (no. of 
cases). 
 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Injecting drugs 583 480 585 524 636 618 659 649 699 575 
Sex 80 73 82 75 83 88 68 90 86 75 
Perinatal 5 3 11 10 10 12 7 4 4 3 
Blood products 8 24 20 5 14 8 7 11 13 14 
Other 45 37 41 47 50 40 32 40 35 38 
Unknown 480 575 432 417 378 401 406 379 396 471 
Total 1,201 1,192 1,171 1,078 1,171 1,167 1,179 1,173 1,233 1,176 
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Figure 11. Hepatitis C by age group, 2006–2015 (no. of cases). 
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Figure 12. Incidence of hepatitis C (cases/100,000 population) by hospital district, 2015.  
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Sexually transmitted diseases 
 
 
• No significant changes have occurred in the number of chlamydia infections in the past five 
years.  
• The number of gonorrhoea infections was almost equal to that of the previous year. More 
than half of the infections were acquired in Finland.  
• The number of syphilis infections has increased in the last couple of years. The 249 cases 
diagnosed is the highest ever reported to the National Infectious Diseases Register.  
• The number of HIV cases has not changed significantly in the past decade. In Finland, HIV is 
mainly a sexually transmitted disease, as the number of infections acquired through the use of 
intravenous drugs was below ten. 
• No mother to child infections of Finnish origin have been diagnosed in screenings at maternity 
clinics. 
• The number of new AIDS cases was 18, most being related to the late diagnosis of the 
infection. 
• A significant percentage of syphilis, gonorrhoea and HIV infections contracted by Finnish men 
were the result of sexual contact between men. 
 
 
CHLAMYDIA  
(CHLAMYDIA TRACHOMATIS) 
In 2015, a total of 13,571 cases of chlamydia were 
diagnosed. No significant changes have occurred in 
the number in the past five years. The highest num-
ber of cases (34%) was reported in the Hospital 
District of Helsinki and Uusimaa, but the incidence 
was highest (315/100,000) in the Hospital District of 
Lapland.  
Typically for chlamydia, most cases were diagnosed 
in women and young adults: 58% of infections were 
reported in women and 81% in the age group 15‒29. 
The incidence was highest (1,646/100,000) in the 
age group 20 to 24. One quarter of the infections in 
women was diagnosed in young individuals (age 
group 15‒19); the corresponding share in men was 
lower at 11%. The majority (92%) of infections were 
diagnosed in individuals of Finnish origin.  
LGV (LYMPHOGRANULOMA  
VENEREUM) 
Two cases of LGV, caused by Chlamydia tracho-
matis, were reported in 2015. Both cases involved a 
Finn, the mode of transmission being sexual contact 
between men abroad. Reporting of LVG cases began 
in 2011. All in all, 20 infections have been reported, 
all in men and 17 in Finns. The mode of transmis-
sion is known for 19 cases, being sexual contact 
between men in all of them. 
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Figure 13. Chlamydia cases in the young adult age groups, 2006–2015 (no. of cases). 
 
GONORRHOEA (NEISSERIA GONOR-
RHOEAE) 
In 2015, 281 gonorrhoea infections (5.1/100,000) 
were diagnosed, an almost equal number to that of 
the previous year. The highest number of infections, 
accounting for 61% of all cases, was reported in the 
Helsinki and Uusimaa Hospital District, where the 
incidence was also highest, at 10.8/100,000. 
The majority of infections (77%) was reported in 
men. The cases were most frequent in the age group 
20–35, accounting for 66% of all cases. The inci-
dence was highest (20.3/100,000) in the age group 
25 to 29. The majority (75%) of infections were 
diagnosed in individuals of Finnish origin. 
The country of acquisition was reported in 78% of 
cases, being Finland in 63%. As in previous years, 
the majority of infections contracted abroad origi-
nated in Thailand. Of these, all but one were diag-
nosed in Finns. 
The gender of the sexual contact was reported in 
79% of the cases. The percentage of sexual contact 
between men was significant,  
as 64% of infections among men were contracted in 
this way. The majority (74%) were contracted in 
Finland. 
Antimicrobial susceptibility was known in less than 
half of the gonorrhoea cases in 2014. Sufficient 
doses of ceftriaxon are still efficient in treating gon-
orrhoea, as by the end of 2014 no Gonococcus 
strains resistant to ceftriaxon had been reported in 
Finland. 
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Table 3. Gonorrhoea infections acquired domestically and abroad, 2006–2015 (no. of cases). 
 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Finland 107 78 88 113 124 136 165 154 144 139 
Thailand 41 44 34 37 44 36 37 31 22 27 
Spain 4 1 0 5 6 3 3 6 8 9 
Germany 2 2 0 3 5 5 4 4 4 7 
Russia 10 5 13 7 7 5 7 3 2 2 
Other country 18 19 24 32 26 47 56 39 58 36 
Unknown 50 43 39 39 41 52 43 27 48 61 
Total 232 192 198 236 253 284 315 264 286 281 
 
 
SYPHILIS (TREPONEMA PALLIDUM) 
The 249 syphilis infections (4.6/100,000) diagnosed 
in 2015 is the highest annual number so far reported 
to the National Infectious Diseases Register. The 
number of cases reported includes both active syphi-
lis infections and old serological scars. Of the cases, 
almost one half (47%) were reported in the Helsinki 
and Uusimaa Hospital District, the incidence being 
7.4/100,000.  
The majority of infections (74%) were reported in 
men. Cases were most frequent in the age group 25–
49, accounting for 67% of all cases. The incidence 
was highest (11.6/100,000) in the age group 35 to 
39.  Individuals of foreign origin accounted for 55% 
of the cases. 51 cases (2014: 29) were diagnosed in 
individuals who do not have a Finnish identity num-
ber. The growth in this group is partially explained 
by the fact that asylum seekers arriving in Finland 
have been actively screened for the disease. 
The country of acquisition was reported in 63% of 
the cases, of which 62% were infections acquired 
abroad. However, infections acquired in the home 
country dominated by a share of 70% in individuals 
of Finnish origin.  
The gender of the sexual contact was reported in one 
half of the cases. The percentage of sexual contact 
between men was significant, 
as 74% of infections among men were contracted in 
this way. Of these, more than one half, 58%, were 
acquired in Finland. 
Table 4. Syphilis infections acquired domestically and abroad, 2006–2015 (no. of cases). 
 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Finland 21 57 57 69 36 37 56 25 45 62 
Somalia 3 4 7 10 5 10 5 3 1 12 
Russia 17 16 25 18 26 19 29 22 23 11 
Estonia 5 5 9 3 9 4 7 4 11 9 
Iraq 0 0 3 3 2 2 2 3 1 8 
Spain 1 2 3 1 5 2 3 5 2 8 
Thailand 1 2 6 5 4 6 6 5 8 7 
Other country 68 22 30 26 40 35 34 19 45 45 
Unknown 20 78 73 65 78 62 65 69 67 87 
Total 130 186 213 200 205 177 207 155 203 249 
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HIV AND AIDS 
In 2015, 173 new HIV infections were diagnosed 
(incidence 3.2/100,000). More than half, 53%, were 
reported in the Helsinki and Uusimaa Hospital Dis-
trict, where the incidence was also highest, at 
5.8/100,000. Eighteen cases of AIDS were diag-
nosed. No deaths due to HIV infection were report-
ed. 
Of HIV infections, 75% were diagnosed in men, 
25% in women. Individuals of foreign origin ac-
counted for 56% of all cases. The majority of infec-
tions (90%) in Finns was reported in men, but the 
percentage of women, 36%, was higher among indi-
viduals of foreign origin. HIV is one of the infec-
tions screened in asylum seekers arriving in Finland. 
The number of HIV findings in persons who do not 
have a Finnish identity number has not increased in 
recent years, being 16 cases in 2015. 
The majority of infections (68%) were acquired 
through sexual contact. Infections acquired through 
heterosexual contact accounted for 41% and sexual 
contact between men for 27% of these cases. Infor-
mation on the mode of transmission was lacking in 
25% of cases.  
The reported number of infections contracted 
through heterosexual contact was 72, 61% being in 
men. Of these, individuals of foreign origin account-
ed for 57%. The majority (78%) of cases, among 
both Finns and foreigners, for which the country of 
infection was known were contracted abroad. As in 
previous years, Thailand was a prominent source of 
infection for Finns who had acquired the infection 
abroad. 
The number of infections due to sexual encounters 
between men was 47. Of these, individuals of Finn-
ish origin accounted for 62%. The majority (70%) of 
cases among Finns, for which the country of infec-
tion was known, were contracted in the home coun-
try.  
Seven cases were diagnosed in which the infection 
was related to intravenous drug use, six of these in 
individuals of foreign origin. Infections of foreigners 
had all been contracted abroad. Since the epidemic 
at the turn of the millennium, efficient prevention 
methods have helped to keep the number of infec-
tions contracted in Finland at a low level. 
Three mother to child infections were reported, all of 
foreign origin. A total of 44 infections were detected 
in maternity clinic screenings; in most of these, the 
HIV infection was known before pregnancy. The 
eight new cases diagnosed account for 19% of all 
HIV infections detected in women in 2015. Because 
of comprehensive screening at maternity clinics, and 
efficient HIV medication, no mother to child infec-
tions have been diagnosed in Finland since 2000.  
One infection caused by blood products was report-
ed in a foreign individual. Since HIV testing of do-
nated blood began in Finland in 1985, no infectios 
through blood products  cases have been reported of 
in Finland. 
In 2015, 18 new cases of AIDS were reported, ten in 
individuals of Finnish and eight of foreign origin. In 
the majority of cases, AIDS was related to the late 
diagnosis of the infection. The reported number of 
HIV positive patients who died totalled 24, but no 
deaths due to the HIV infection were reported. 
The CD4 value at the time the infection was diag-
nosed was reported in 83% of the cases. The per-
centage of late detection of infections (CD4 lower 
than 350) was 51%. The challenge therefore lies in 
detecting HIV infections earlier than at present.  
By the end of 2015, the total number of HIV infec-
tions diagnosed in Finland was 3,513. The reported 
number of HIV positive patients who died was 442, 
but because of efficient HIV medication, the majori-
ty of deaths in the 2000s were due to reasons other 
than HIV. 
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Figure 14. HIV cases by mode of transmission, 2006–2015 (no. of cases). 
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Antimicrobial resistance 
 
 
• The number of MRSA infections was slightly lower than in the previous year, which was also 
revealed in blood culture findings. 
• A previously rare strain of MRSA CC398, linked to production animals, was detected in 41 
individuals in Finland.    
• The number of VRE cases continued to decline, as only one blood culture finding was made 
and VRE findings in blood have been rare in general. 
• The growth in the total number of ESBL E. coli findings seems to have come to a halt, as the 
number of findings has decreased in the age group 75 and older, but growth continued in 
younger age groups. 
• The number of CPE findings doubled over 2014, with approximately one half of the CPE 
infections being acquired abroad.  
 
 
MRSA 
In 2015, 1,274 new cases of MRSA (methicillin-
resistant Staphylococcus aureus) were reported, 
slightly fewer than in the year before (2014: 1,342). 
The number of MRSA cases confirmed through 
blood culture findings was also lower than in the 
previous year (2015: 40; 2014: 46). Of the MRSA 
blood culture findings, 21 were in the Helsinki and 
Uusimaa Hospital District (1.3/100,000), while other 
hospital districts reported zero to three cases, total-
ling 19. Most (35/40) of the invasive cases occurred 
in men and in the age group 20‒65 (23/40), only one 
occurred in children. The total number of cases was 
highest in the hospital districts of Helsinki and 
Uusimaa and Pirkanmaa, as were the incidence fig-
ures. As before, almost 40 per cent of the findings 
were related to patients aged 65 or over. The number 
of MRSA cases in children increased (2015:140; 
2014: 108). 
Patients arriving at hospital are screened for MRSA 
if they have been in a refugee camp or hospitalised 
abroad in the last 12 months. In 2015, 110 patients 
who did not have a Finnish identity number were 
diagnosed as MRSA carriers (2014: 20 findings). 
This group is highly likely to include not only tour-
ists, but a significant number of asylum seekers as 
well. 
The MRSA strain was typed in 1,348 individuals. 
There were 247 different spa types among the 
MRSA strains (2014: 205). The three most common 
spa types were the same as in previous years: t172 
16% (2014: 19%), t008 8% (2014: 11%) and t067 
6% (2014: 10%).  The next most common spa types 
were t304, t127 and t002 (4% of each).  Of these, the 
proportion of t304 (2014: 1%) and t127 (2014: 2%) 
has increased markedly in 2015. t172 was present in 
17 hospital districts. As in previous years, the oc-
curence of spa type t067 was most frequent in Pir-
kanmaa and the Hospital District of South Ostro-
bothnia, but the occurence of this strain continued its 
clear decline in 2015. In addition, local clusters were 
caused, among others, by t010, t032 and t020 in the 
Helsinki and Uusimaa Hospital District. 
The two most common spa types among patients 
over 75 were t172 at 21% (2013: 19%) and t067 
12% (2014: 17%). The most common spa types 
among children under the age of 16 were t127 at 9% 
(2014: 2%), t044 at 8% (2014: 8%) and t008 7% 
(2014: 14%).  
An invasive MRSA strain was typed in 38 individu-
als. The most common spa types were t172 (2015: 
10 and 2014: 6) and t008 (2015: 6 and 2014: 6). 
There were two cases of spa types t002, t026 and 
t10993, and the remaining cases (16/38) each repre-
sented different spa types. 
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In 2015, four MRSA strains with the mecC gene 
were isolated from clinical samples (2014: 6), of 
which one was isolated from blood.  Of the strains, 
three were spa type t843 and one spa type t742.  
In recent years, spa types of the MRSA CC398 
complex, related to production animals, have be-
come increasingly common in Europe. These strains 
have so far been rare in Finland. In 2007–2014, 48 
strains of the CC398 complex were typed. In 2015, 
however, the number of strains clearly increased 
compared to the previous situation, as CC398 
MRSA was typed in the case of samples from 41 
individuals. 
Spa type t034 is clearly the most common strain of 
the CC398 complex in Finland, and its numbers 
considerably increased last year (2015: 33, 2014: 14, 
2013: 5, 2012: 2). So far, there have been three 
MRSA CC398 findings in blood in Finland (2015: 
t034 and t1250; 2013: t12593). Other spa types of 
the CC398 complex found in Finland include t011, 
t108, t571, t899, t2582 and t2741. 
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Figure 15. MRSA cases by hospital district and by year 2006–2015 (no. of cases). 
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Table 5. MRSA findings and their percentage of S. aureus blood culture findings, 1995–2015  
(no. of cases and %). 
Year MRSA findings S.aureus blood culture findings MRSA blood culture findings and S.aureus  methicillin resistance (%) 
1995 89 627 2 (0.3) 
1996 110 667 0(0.0) 
1997 121 747 4 (0.5) 
1998 190 719 5 (0.7) 
1999 212 813 8 (1.0) 
2000 266 850 4 (0.5) 
2001 340 887 4 (0.5) 
2002 600 989 9 (0.9) 
2003 859 981 7 (0.7) 
2004 1,479 1,059 30 (2.8) 
2005 1,374 1,013 27 (2.7) 
2006 1,331 1,240 37 (3.0) 
2007 1,254 1,179 33 (2.8) 
2008 1,728 1,260 40 (3.2) 
2009 1,266 1,289 30 (2.3) 
2010 1,267 1,374 26 (1.9) 
2011 1,328 1,484 43 (2.9) 
2012 1,287 1,492 30 (2.0) 
2013 1,282 1,590 29 (1.8) 
2014 1,342 1,925 46 (2.4) 
2015 1,274 2,051 40 (2.0) 
 
 
VRE 
The number of reported cases of the vancomycin-
resistant enterococcus (VRE) in 2015 decreased on 
the previous year (2015: 13, 2014: 32) The number 
of findings in hospital districts varied from zero to 
three. One of the findings was based on a blood 
sample. In fact, VRE has rarely been found in blood 
overall (2014: 0, 2013: 0, 2012: 1).  
Of the total of 15 VRE findings sent to the microbial 
strain collection, 13 were of the species E. faecium 
and two E. faecalis. More vanB than vanA genes 
were found in these species (vanB 11; vanA 4). In 
addition, one strain of E. raffinosus with an acquired 
vanA gene was identified.  
ESBL – ESCHERICHIA COLI AND  
KLEBSIELLA PNEUMONIAE 
Since the beginning of 2008, third-generation Esche-
richia coli and Klebsiella pneumoniae exhibiting 
reduced susceptibility or resistance to cephalosporin 
(I for intermediate and R for resistant, respectively) 
have been reported to the NIDR. An estimated 90 
percent of these bacteria are extended-spectrum 
beeta-lactamase-producing, so-called ESBL strains 
that split penicillin andcephalosporins. 
In 2015, the majority of findings were E. coli (4,175; 
in 2014: 4,190), and a small minority of K. pneu-
moniae strains (288; in 2014: 312). E. coli ESBL 
findings were made in all age groups, 72% in  
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women and almost one half in patients aged 65 or 
more. More than one half of findings (58%, 
2,417/4,175) were based on urine cultures. The larg-
est number of cases was found in the Hospital Dis-
trict of Helsinki and Uusimaa (1,332, 83/100,000), 
but the incidence was highest in the Åland Islands 
(138/100,000) and Kymenlaakso (111/100,000) 
hospital districts. The number of blood culture find-
ings equalled the figures for 2014 (232 cf. 232) (the 
ESBL proportion in E. coli blood cultures: 
232/4,532, 5.1% cf. 5.3% in 2014). Of these, 27% 
were in the Hospital District of Helsinki and 
Uusimaa. However, the incidence of blood culture 
findings was highest in the Hospital District of Vaa-
sa. 
More than 50% of ESBL findings involving K. 
pneumoniae were diagnosed in patients aged 65 or 
over but, at 63 per cent, the percentage of women 
was smaller than with E. coli ESBL findings. Al-
most one half of diagnoses (48%, 137/288) were 
based on urine. The largest number of cases were 
recorded in the hospital districts of Helsinki and 
Uusimaa (86) and Southwestern Finland (34), while 
the incidence was highest in the Länsi-Pohja and 
Kainuu hospital districts. Fifteen (2014: 20) of the 
findings were based on blood (the ESBL proportion 
in the K. pneumoniae blood cultures: 2015: 15/654, 
2.3% cf. 2014: 3.2%). 
As a whole, the increase in the number of E. coli 
findings exhibiting resistance to third-generation 
cephalosporin seems to have to come to a halt in 
Finland. The reason for this is reduced resistance in 
patients aged 75 or more. In younger age groups, the 
steady increase in resistance continued, which indi-
cates continuing growth in the percentage of carriers 
within the healthy population. A decrease in E. coli 
ESBL strains isolated from blood is evident in older 
age groups, but as a whole, the incidence in blood 
and cerebrospinal fluid findings continued to grow, 
however not as intensely as before.  
In 2015, an E. coli ESBL finding was made in 194 
individuals with no Finnish identity number (2014: 
69 findings), and K. pneumoniae ESBL finding in 24 
(2014: 7 findings). This increase may partly be ex-
plained by the screening of bacteria resistant to an-
timicrobials in patients arriving in hospital, includ-
ing not only tourists but probably a significant num-
ber of asylum seekers. 
Table 6. E. coli findings with reduced susceptibility to third-generation cephalosporins (possible ESBL, 
extended-spectrum β-lactamase) and ESBL percentage, 2008–2015 (no. of cases and %). 
 ESBL findings E. coli blood culture findings ESBL E. coli blood culture findings and  
percentage of ESBL E. coli (%) 
2008 1,674 2,814 43 (1.5) 
2009 2,177 2,989 77 (2.6) 
2010 2,559 3,226 111 (3.4) 
2011 3,138 3,475 149 (4.3) 
2012 3,686 3,463 203 (5.9) 
2013 4,464 3,876 233 (6.0) 
2014 4,190 4,366 232 (5.3) 
2015 4,175 4,532 232 (5.1) 
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Table 7. K. pneumoniae findings with reduced susceptibility to third generation cephalosporins (possible 
ESBL, extended-spectrum β-lactamase) and ESBL percentage, 2008–2015, (no. of cases and %).
ESBL findings K. pneumoniae blood
culture findings
ESBL K. pneumoniae blood culture findings and 
percentage ESBL K. pneumoniae (%) 
2008 116 418 3 (0.7) 
2009 156 480 6 (1.3) 
2010 190 508 16 (3.1) 
2011 242 453 10 (2.2) 
2012 242 583 10 (1.7) 
2013 238 570 12 (2.1) 
2014 312 634 20 (3.2) 
2015 288 654 15 (2.3) 
Figure 16. Incidence of E. coli findings (cases/100,000 population) with reduced susceptibility and resistance to 
third-generation cephalosporins (possible ESBL, extended-spectrum β-lactamase) by age group 2008‒2015. 
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Figure 17. Incidence of E. coli findings (blood and cerebrospinal fluid findings /100,000 population) with reduced 
susceptibility and resistance to third-generation cephalosporins (possible ESBL, extended-spectrum β-
lactamase) by age group 2008‒2015. 
CPE (CARBAPENEMASE-  
PRODUCING ENTEROBACTERIA) 
In 2015, 55 findings were reported to the National 
Infectious Diseases Register showing enterobacteria 
with reduced susceptibility (intermediate, I) or re-
sistance (resistent, R) to carbapenemase, i.e. the 
bacterial strain was possibly CPE. Of the findings 
reported, 25 were E. coli, 20 Klebsiella pneumoniae 
and 10 Enterobacter cloacae. Of the reported find-
ings, in 39 cases the bacterial strain was sent for 
confirmation tests to the laboratory of the National 
Institute for Health and Welfare. Of the strains sent, 
24 were actual CPE strains. In addition, 139 possible 
CPE strains were sent to the National Institute for 
Health and Welfare, of which five proved to be car-
bapenemase-producing. The total number of actual 
CPE findings was 29, which meant that the number 
of findings doubled over 2014. Most findings in-
volved K. pneumoniae strains (14), but E. coli was 
common as well (10). In addition to these, other 
individual species of enterobacteria with the car-
bapenemase gene were isolated in 2015, including 
three strains of Citrobacter freundii (KPC, VIM, 
GES). In 2015, the most common carbapenemases 
were KPC and NDM, and the OXA-48 group was 
the third most common (10, 10 and 6).  
More than half of the CPE infections were probably 
acquired abroad, particularly in Asia and Southern 
Europe. The cluster caused by a KPC-positive K. 
pneumoniae (ST512), detected in 2015 but probably 
initiated back in 2013, explains the high percentage 
of domestic ones.  The majority of CPE strains were 
isolated in colonisation samples. The median age of 
patients was 64. 
The number of CPE cases is still very low in Fin-
land, but increasing slightly. K. pneumoniae is the 
most common finding (about 60% of all findings). 
Species with reduced susceptibility to car-
bapenemase, reported to the National Infectious 
Diseases Register, account for over 90% of all CPE 
findings in Finland. Until now, KPC positive K. 
pneumoniae strains have caused all clusters diag-
nosed in care facilities in Finland. The role of other 
species in terms of hospital hygiene remains unclear. 
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Table 8. Carbapenemase-producing enterobacteria (CPE), 2009–2015, (no. of cases). 
 CPE findings 
 New bacterial strains New patients 
2009 5 5 
2010 8 8 
2011 12 11 
2012 9 8 
2013 21 20 
2014 17 14 
2015 29 29 
 
 
Table 9. Carbapenemase-producing enterobacteria (CPE) and possible foreign contact 2015, (no. of cases). 
Country Patients Genes 
No contact/not 
known 14 6 KPC*, 4 OXA-48 groups, 2 NDM, 1 VIM, 1 GES 
India 4 NDM 
Greece 3 2 KPC, 1 VIM 
Egypt 1 NDM 
Spain 1 KPC 
Italy 1 KPC 
Canary Islands 1 OXA-48 
Croatia 1 NDM 
Cuba 1 NDM 
Thailand 1 IMP 
Tunisia 1 OXA-48 
 
*Epidemic 
 
Table 10. The most common types of gene combinations for Carbapenemase-producing enterobacteria (CPE) in 
Finland 2009–2015, (no. of cases). 
 KPC NDM OXA-48 VIM 
K. pneumoniae 30 10 10 5 
E. coli 2 19 9 0 
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Tuberculosis 
 
 
• There were around ten more cases of tuberculosis than in 2014. 
• All children who contracted tuberculosis were of foreign origin. 
• The percentage of foreigners among patients contracting tuberculosis was 39%, up by one 
fifth year-on-year. 
• The number of tuberculosis drug-resistant Mycobacterium tuberculosis strains has increased 
slightly in recent years. 
 
 
TUBERCULOSIS (MYCOBACTERIUM 
TUBERCULOSIS) 
Incidence of tuberculosis 2015 
The number of tuberculosis cases was 271 
(5.0/100,000), 11 (4%) cases more than in 2014 
(260; 4.8/100,000). Of these, 195 (72%) were cases 
of pulmonary tuberculosis, 62 (32%) of which pro-
duced a positive sputum stain test. There were 215 
cases of tuberculosis confirmed by culture (62%), 
two more than in 2014 (213).  
The increase in the overall number of tuberculosis 
cases in Finland in 2007 and 2008 compared to 2006 
can be explained by the introduction in 2007 of the 
broader EU definition of tuberculosis cases. The 
annual numbers of cases confirmed by culture are 
comparable throughout the monitoring period. The 
number of these cases remained stable from 2007 to 
2011 except in 2009, when an exceptionally large 
number of cases in foreigners was recorded; in 
2012–2015, however, the figure became stable 
again.  
The distribution of cases by age group was as fol-
lows: under 15, 12 (4%); 15 to 29, 65 (24%); 30 to 
44, 43 (16%); 45 to 59, 24 (9%); 60 to 74, 50 (19%); 
and over 75, 77 (29%). Population reduction among 
the age groups in whose youth the incidence of tu-
berculosis in Finland was high, and the increasing 
number of young immigrants, has led to a notable 
decrease in the average age of tuberculosis patients 
between 2000 and 2015, from 64 to 52 years.  In 
2015, all 12 children who were diagnosed with tu-
berculosis were of foreign origin. 
The patient was reported to be foreign in 105 cases 
(39%), i.e. born abroad and assumed to have other 
than Finnish citizenship unless the data indicate 
otherwise. This was 19 (22%) more than in the pre-
vious year. The distribution of these cases by age 
group was as follows: under 15, 7(7%); 15 to 29, 51 
(49%); 30 to 44, 32 (30%); 45 to 59, 11 (10%); and 
over 60, 4 (4%) (Figure 18). Among these, there 
were 77 cases (73%) of pulmonary tuberculosis and 
28 cases (27%) of other forms of tuberculosis. In-
formation on the patient’s country of birth or citi-
zenship was missing in 17 cases (6%). 32 cases 
(12%) were diagnosed in individuals who do not 
have a Finnish identity number. Some of them are 
likely to be asylum seekers. The corresponding fig-
ure was six the year before. 
In four (1%) of the tuberculosis cases reported in 
2015, the patient also had an HIV infection. In one 
of these cases, the HIV infection was reported as a 
new case in 2015, while the HIV infection of the 
three other cases had been registered before. Three 
persons were of foreign and one of Finnish origin. 
Tuberculosis strain susceptibility to medi-
cation in 2015 
Although susceptibility to medication is still fairly 
good, the number of Mycobacterium tuberculosis 
strains resistant to tuberculosis medication has 
grown. Of all cultured strains, 89% had full suscep-
tibility and, in 24 cases, resistance to one or several 
drugs was diagnosed. Of the eight MDR cases diag-
nosed during the year, one case was an extended-
drug resistant (XDR) tuberculosis. One of the MDR 
cases was in a patient born in Finland, others were 
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from Somalia, Estonia, Russia and Afghanistan. 
Four MDR cases were diagnosed in asylum seekers. 
Tuberculosis genotyping findings 2015 
Mycobacterium tuberculosis strains were analysed 
using the internationally standardised spoligotyping 
and MIRU-VNTR methods. The most common 
spoligotypes were SIT53 and the so-called Beijing 
type SIT1, 25 of each were detected (12%). Clusters 
sharing the same spoligo and MIRU-VNTR type 
totalled 40, including a total of 68 strains, 34% of 
the total number of strains typed. The most common 
cluster, which even caused exposure in a school in 
Oulu, was of genotype SIT1 (7 cases). The second 
most common cluster was the so-called Nordic clus-
ter, with five new cases in various parts of the coun-
try.  
Tuberculosis outcome surveillance in 
2010-2014 
Table 12 shows the distribution of treatment out-
comes between 2010 and 2014. The domain consists 
of cases of pulmonary tuberculosis confirmed by 
culture, genetic replication or staining. Cases where 
the pathogen is an MDR strain are reported separate-
ly and are not included in Table 12. An outcome 
evaluation is performed 12 months after the case is 
registered.  
A significant number (63) of outcome evaluation 
reports for 2014 were missing when the annual re-
port was written, but the treatment outcome was 
good in 76% of cases in 2013. This falls clearly 
short of the international target set by the WHO at 
85%, but is on a par with the average for most EU 
Member States.  Mortality (before beginning treat-
ment or during treatment) was 17% in 2013. 
Other mycobacteria 
A total of 670 non-tuberculotic, environmental my-
cobacteria were identified (incidence 12.3/100,000). 
The most common of these found in patient samples 
were Mycobacterium avium (n=192), Mycobacte-
rium gordonae (n=156) and Mycobacterium intra-
cellulare (n=84), ten of which were diagnosed in 
children under the age of 5. 
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Table 11. Incidence of tuberculosis (cases/100,000 population) and percentage of culture-confirmed cases in Finland, 1995–2015 (no. of cases and %). 
 Pulmonary tuberculosis  Other tuberculosis All cases Foreigners 
 Cases Incidence 
Cases with 
positive 
sputum 
smear 
Incidence Cases Incidence Cases Incidence Culture-confirmed 
Culture-
conf.% Cases % 
1995 436 8.6 243 4.8 223 4.4 659 12.9 472 71.6 30 4.6 
1996 451 8.8 243 4.7 206 4.0 657 12.8 511 77.8 36 5.5 
1997 359 7.1 188 3.7 214 4.3 573 11.4 440 76.8 43 7.5 
1998 399 7.8 207 4.0 213 4.1 612 11.9 493 80.6 50 8.2 
1999 399 7.7 183 3.5 193 3.7 592 11.5 506 85.5 41 6.9 
2000 372 7.2 225 4.4 170 3.3 542 10.5 455 83.9 42 7.7 
2001 316 6.1 155 3.0 182 3.5 498 9.6 416 83.5 58 11.6 
2002 297 5.7 136 2.6 178 3.4 475 9.1 394 82.9 44 9.3 
2003 293 5.6 147 2.8 122 2.3 415 8.0 351 84.6 39 9.4 
2004 233 4.5 127 2.4 102 2.0 335 6.4 291 86.9 33 9.9 
2005 269 5.1 137 2.6 103 2.0 372 7.1 324 87.1 41 11.0 
2006 206 3.9 99 1.9 90 1.7 296 5.6 271 91.6 47 15.9 
2007 229 4.4 93 1.8 118 2.2 347 6.6 251 72.3 67 19.3 
2008 213 4.0 105 2.0 127 2.4 340 6.4 246 72.4 46 13.5 
2009 289 5.5 94 1.8 124 2.4 413 7.9 303 73.4 116 28.1 
2010 225 4.2 85 1.6 92 1.7 317 5.9 250 78.9 101 31.9 
2011 232 4.3 84 1.6 92 1.7 324 6.0 252 77.8 80 24.7 
2012 194 3.6 83 1.5 82 1.5 276 5.1 223 80.8 81 29.3 
2013 213 3.9 92 1.7 58 1.1 271 5.0 204 75.3 87 32.1 
2014 196 3.6 80 1.5 64 1.2 260 4.8 213 81.9 86 33.1 
2015 195 3.6 62 1.1 76 1.4 271 5.0 215 61.6 105 38.7 
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Table 12. Results of outcome evaluation for treatment of microbiologically confirmed pulmonary tuberculosis, 
2009–2014 (no. of cases and %). 
 2010 2011 2012 2013 2014 
Favourable 149 (80%) 131 (70%) 122 (74%) 142 (76%) 73 (44%) 
Cured 94 74 63 82 44 
Treatment completed 55 57 59 60 29 
Non-favourable 22 (12%) 38 (20%) 27 (16%) 33 (18%) 23 (14%) 
Deceased 18 37 27 32 22 
Interrupted treatment 4 0 0 0 1 
Treatment failure 0 1 0 1 0 
Missing 15 (8%) 17 (9%) 16 (10%) 12 (6%) 72 (42%) 
Transfer 2 7 7 3 4 
Treatment continues at 12 months 8 8 8 4 5 
Unknown 5 2 1 5 63 
Total 186 186 165 187 168 
 
 
 
Figure 18. Tuberculosis cases by age group and origin in 2015, (no. of cases). 
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Other infections 
 
 
• Around a hundred more cases of severe pneumococcal infection were diagnosed than in 
2014.  
• The incidence of serotypes not included in the pneumococcal conjugate vaccine increased in 
the adult age groups. In patients aged 65 or older, 80% of cases were caused by serotypes 
not included in the vaccine. The ageing of the population and possible changes in disease 
diagnostics and the prevalence of the risk factors of pneumococcal disease may contribute to 
the increase. 
• The number of meningococcus infections was on a par with the previous year. Serogroups C 
and Y caused infections, particularly in young people in the age group 15–19 and serogroup 
W in adults. 
• Four adults in the same workplace, born before the MMR vaccinations were introduced, 
contracted rubella. 
• A record number of borrelia cases was reported and the incidence is highest in the autumn, 
from August to October.  
• The number of tick-borne encephalitis (TBE) cases, almost 70, was also record-high. In 
mainland Finland, most TBE infections were contracted in known risk areas. Porkkala, Oulu, 
Ilomantsi, Muurame, the Rauma archipelago and Vierumäki  emerged as new potential areas 
of infection.  
• Fewer cases of Puumala virus were reported than in 2014. More than half of the patients 
were men, the majority being of working age. 
• Only 15 cases of Pogosta disease were reported, the lowest figure ever in the history of the 
National Infectious Diseases Register. 
• A total of 32 people were exposed to rabies abroad, mainly in Thailand. More than half of the 
cases of exposure abroad were related to a dog bite. 
• All cases of malaria originated in Africa. Approximately one half of the patients were 
immigrants coming from a malarious area, who had travelled in their former home region. 
None of the patients who fell ill had used the appropriate prophylaxis. 
• Almost 15,000 bacterial findings were detected in cultured blood samples from adults. These 
findings have constantly increased, particularly in patients aged 65 or over. Escherichia coli 
was the most common finding in both the working age population and in patients aged 65 
and older. Other common findings include Staphylococcus aureus, of which a significant 
percentage is known to be treatment-related infections. 
• The number of early-onset GBS cases in newborns was record-breakingly low at 13 (0.2 cases 
per 1,000 live births). This is probably due to improved preventive practices. 
 
 
INVASIVE PNEUMOCOCCAL DISEASE 
(STREPTOCOCCUS PNEUMONIAE) 
The reported number of invasive, severe cases of 
pneumococcal disease, in which the pathogen was 
identified in a blood or cerebrospinal fluid cul-
ture,was 815 (14.9/100,000). This is approximately a 
hundred more than in 2014 (703; 12.9/100,000). In 
addition, the number of cases reported on the basis 
of nucleic acid detection totalled only 9. No serotype 
data is available for these cases and they are not 
included in the statistics below.  
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The incidence of pneumococcal disease continued to 
decrease in under 18-year-olds, but increased in the 
older age groups (table 13). Of the patients, 2.8% 
were under the age of 5 and 52.4% over 65. As be-
fore, the incidence was higher among men than 
among women (16.3 cf. 13.5/100,000). Variation in 
incidence between hospital districts more than quad-
rupled (6.9–29.9/100,000), which may be due to 
differences in how actively blood cultures are taken.  
The serotype of 800 (98%) cases of pneumococcal 
disease confirmed by culture was identified. These 
cases were divided into 39 serotypes or serogroups. 
As in the previous year, serotype 3, caused almost 
one fifth (145; 17.8%) of all cases. The next most 
common serotypes were 19A (139; 17.1%) and 22F 
(79; 9.7%) (figure 19). These three were common 
pathogens, particularly in the elderly, as was sero-
type 19A in children under the age of 5, in whom it 
caused 57% (13/23) of all infections. Together, they 
caused 45% of all cases (in 2014, 41%). Compared 
with the previous year, serotypes 19A increased 
most (2015: 139 cf. 2014: 95), 6C (40 cf. 13) and 3 
(145 cf. 121). 
The 10-valent pneumococcal conjugate vaccine 
(PCV10) has been included in the national basic 
vaccination programme for children since September 
2010. Severe pneumococcal diseases caused by 
serotypes in the PCV10 vaccine (1, 4, 5, 6B, 7F, 9V, 
14, 18C, 19F, 23F) have almost been eliminated in 
young children and continued to decrease in 2015, 
particularly in the 5 to 17, 18 to 64 and 65 and over 
age groups, compared to the years (2006–2009) 
which were prior to the introduction of the vaccine. 
This is an indirect consequence of the vaccination 
programme for children. In children under 2 years of 
age, one case caused by PCV10 serotypes was diag-
nosed in an unvaccinated child. Moreover, three 
other infections caused by PCV10 serotypes were 
diagnosed in older children (table 14). 
The incidence of serotypes not included in the 
PCV10 vaccine increased in the adult age groups,  
particularly cases caused by serotypes 19A, 6C and 
3. In patients aged 65 or older, 80% of cases were 
caused by serotypes not included in the PCV10 vac-
cine. The ageing of the population and possible 
changes in disease diagnostics and the prevalence of 
the risk factors of pneumococcal disease may con-
tribute to an increase in disease incidence. For more 
detailed statistics by age and serotype, please see the 
National Institute for Health and Welfare website.  
Antimicrobial sensitivity was determined for 840 
strains of invasive pneumococcus (Table 15). Strains 
with reduced susceptibility to penicillin (MIC > 0.06 
mg/L) accounted for 15% of the strains, and three 
strains completely resistant to penicillin (MIC > 2 
mg/L) were found. The percentage of macrolide-
resistant strains continued to decrease; 14% of inva-
sive pneumococcal strains were resistant to erythro-
mycin. Multiresistant strains (PEN IR–ERY R–TET 
R) accounted for 5% of the strains. One strain of 
pneumococcus resistant to levofloxacin (MIC>2 
mg/L) was found in 2015. No strains resistant to 
ceftriaxone (MIC > 2 mg/L) were found. More mul-
tiresistant strains than before were found. 
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Figure 19. Serotypes of Streptococcus pneumoniae findings in blood and cerebrospinal fluid 2015 (no. of 
cases).  
The column ”Other” includes serotypes that caused fewer than 10 cases and the column “Unknown” includes 
cases whose strains the National Institute for Health and Welfare did not receive.  
PCV10 serotypes, turquoise columns. 
 
Table 13. Pneumococci isolated in blood and cerebrospinal fluid 2006–2015, no. of cases and incidence 
(cases/100,000 population). 
 0–1 2–4 5–17 18–64 65– Total 
year Cases I Cases I Cases I Cases I Cases I Cases I 
2006 82 71.3 31 18.4 19 2.3 345 10.5 271 32.3 748 14.2 
2007 78 67.4 45 26.5 20 2.5 351 10.7 291 33.9 785 14.9 
2008 65 55.1 32 18.4 23 2.9 479 14.4 328 37.5 927 17.5 
2009 62 52.2 31 17.6 32 4.2 434 13.0 295 33.1 854 16.3 
2010 61 50.6 41 23.8 17 2.2 410 12.2 304 33.4 833 15.6 
2011 45 37.0 27 15.7 21 2.7 386 11.6 297 31.7 776 14.5 
2012 15 12.3 17 9.4 15 1.9 361 10.8 342 34.9 750 13.9 
2013 19 15.8 14 7.6 14 1.8 358 10.8 319 31.3 724 13.3 
2014 13 11.0 14 7.6 18 2.3 303 9.1 355 33.6 703 12.9 
2015 11 9.5 12 6.5 14 1.8 351 10.6 427 39.2 815 14.9 
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Table 14. Pneumococci isolated in blood and cerebrospinal fluid by age and serotypes 2008–2015, no. of cases and incidence (cases/100,000 population). 
 PCV10 vaccine serotypes  Non-vaccine serotypes  Unknown 
 0–1 2–4 5–17 18–64 65– Total 0–1 2–4 5–17 18–64 65– Total All age groups 
year Cases I Cases I Cases I Cases I Cases I Cases I Cases I Cases I Cases I Cases I Cases I Cases I Cases I 
2006 67 58.3 26 15.42 15 1.8 227 6.9 161 19.2 496 9.4 14 12.2 5 3.0 3 0.4 105 3.2 101 12.5 228 4.3 24 0.5 
2007 63 54.5 38 22.41 12 1.5 226 6.9 176 20.5 515 9.8 15 13.0 5 3.0 6 0.8 116 3.5 111 12.9 253 4.8 17 0.3 
2008 49 41.5 26 14.98 18 2.2 288 8.7 198 22.6 579 10.9 14 11.9 6 3.5 4 0.5 174 5.2 119 13.6 317 6.0 31 0.6 
2009 47 39.6 26 14.75 23 2.9 277 8.3 165 18.5 538 10.3 12 10.1 4 2.3 8 1.0 141 4.2 118 13.2 283 5.4 33 0.6 
2010 51 42.3 35 19.7 10 1.3 244 7.3 168 18.5 508 9.5 8 6.6 5 2.8 5 0.6 148 4.4 122 13.4 288 5.4 37 0.7 
2011 34 28.0 16 8.93 15 1.9 217 6.5 149 15.9 431 8.0 11 9.5 11 6.1 6 0.8 166 5.0 145 15.5 339 6.3 6 0.1 
2012 8 6.6 16 8.82 7 0.9 190 5.7 150 15.3 371 6.9 7 5.8 1 0.6 8 1.3 169 5.6 187 19.9 372 6.9 7 0.1 
2013 6 5.0 3 1.63 9 1.2 163 4.9 113 11.1 294 5.4 13 10.8 11 6.0 5 0.7 191 5.7 206 20.2 426 7.9 4 0.1 
2014 2 1.7 3 1.63 8 1.3 99 3.0 93 8.8 205 3.8 11 9.3 11 6.0 10 1.3 202 6.9 258 24.4 492 9.0 6 0.1 
2015 1 0.9 3 1.64 4 0.5 80 2.4 75 6.9 163 3.0 10 8.6 9 4.9 10 1.3 265 8.3 343 31.5 637 11.7 15 0.3 
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Table 15. Antimicrobial resistance of pneumococcus findings in blood and cerebrospinal fluid, 1998–2015 
(no. of cases and %). 
Year  
Cases reported to the 
National Infectious 
Diseases Register 
Analysed strains Erythromycin (R) 
% 
Penicillin (I+R) 
(%) 
Multidrug resistance 
(%) 
1998 561 84 3.6 0 0 
1999 568 471 5.9 7.2 0 
2000 601 439 8 3.7 1.4 
2001 658 360 18.8 7.5 5 
2002 599 594 16.3 8 3.7 
2003 721 739 21.9 12.7 5.7 
2004 748 748 20.5 9.6 3.7 
2005 735 731 20.5 9.6 4.4 
2006 748 760 27.9 16.4 5.4 
2007 785 794 23.2 14.4 3.5 
2008 927 930 24.5 17.7 3.4 
2009 854 848 28.4 19.9 4.7 
2010 833 819 28.6 23.4 1.7 
2011 776 780 26.8 21.9 2.8 
2012 750 754 22.2 27.7 5 
2013 724 668 16.8 18.7 4 
2014 703 716 14.5 14.8 2.4 
2015 815 840 13.9 14.5 5 
 
I - reduced susceptibility; R - resistant; Multidrug resistance - strains simultaneously resistant to penicillin (I+R),  
erythromycin (R) and tetracyclin (R) 
 
 
HAEMOPHILUS (HAEMOPHILUS  
INFLUENZAE) 
The total of 52 (0.95/100,000) infections caused by 
the Haemophilus influenzae bacterium, diagnosed in 
blood or cerebrospinal fluid, is on a par with the av-
erage of the two previous years. More than a third 
(19/52, 37%) were diagnosed in patients aged 75 
years or over.  
All cases were diagnosed through culture findings. 
As in earlier years, the majority of these (40/52, 77%) 
were caused by unencapsulated strains of Haemophi-
lus influenzae. Only one infection caused by serotype 
b was found, in an adult individual in whose child-
hood the Hib vaccine was not yet part of the national 
vaccination programme. Serotype f caused an infec-
tion in nine people, one of whom was a six-month old 
baby and the other eight were adults. Serotype e 
caused two infections, both in elderly adults.  
Children born in 1985 or later have been given the 
Hib vaccine at their child care clinics. The vaccina-
tion programme has succeeded in effectively reduc-
ing the number of serious infections caused by bacte-
ria of serotype b, and the circulation of bacteria with-
in the population, but cases may still occur in chil-
dren with incomplete vaccination coverage.  
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Table 16. Cases of Haemophilus influenzae by serotype in 2006–2015, (no. of cases). 
 Unencapsulated a b e f Unknown All cases 
2006 26 0 2 0 2 3 33 
2007 44 0 6 1 1 2 54 
2008 33 0 3 0 8 1 45 
2009 30 0 6 2 7 2 47 
2010 30 0 5 2 3 1 41 
2011 57 0 4 2 2 1 66 
2012 73 0 4 0 4 0 81 
2013 40 1 1 1 5 0 48 
2014 48 0 5 0 6 0 59 
2015 40 0 1 2 9 0 52 
 
 
MENINGOCOCCUS (NEISSERIA  
MENINGITIDIS) 
In 2015, the number of meningococcus infections 
detected in blood or cerebrospinal fluid totalled 22 
(0.40/100,000), which is around the same as in 2014. 
Of these cases, one half were diagnosed in men, six 
(27%) in the age group 0–4, seven (32%) in the 15–
19 age group and nine (41%) in the 44–77 age 
group. Twenty cases were diagnosed through a bac-
terial culture finding and two through nucleic acid 
detection. All bacterial strains were serogrouped and 
analysed through full genome sequencing, a method 
introduced in 2015. Eight (40%) were of serogroup 
B, five (25%) of serogroup C, four (20%) of 
serogroup W and three (15%) of serogroup Y; but 
the serogroup for two cases diagnosed through nu-
cleic acid detection remained unknown. The majori-
ty of infections caused by serogroup B were diag-
nosed in young children (3 cases) and patients aged 
40 and over (4 cases). Serogroup C and Y caused 
infections in young people aged 15–19 and 
serogroup W in adults in particular. Closer compari-
son of the bacterial genome revealed two small clus-
ters, one caused by a bacterium of serogroup W and 
the other, serogroup C.  
Except for the strains that caused clusters, most of 
the bacterial strains were different, being based on 
the genotyping results of several different types. 
There were four types of serogroup C strains, of 
which one (C:P1.7,16-29:F3-3:ST-32 (cc32)) caused 
a cluster of two cases in Western Finland. Of the two 
types of serogroup W strains, one (W:P1.18-1,3: F4-
1: ST-2878 (cc22)) caused one case and the other, 
(W:P1.5,2: F1-1: ST-11 (cc11)) three cases in 
Southern Finland. In two of these cases the genome 
of the bacteria was almost identical.  Since the bac-
terial clone W:P1.5,2: F1-1: ST-11 (cc11) has be-
come more common in recent years, particularly in 
England and Wales, in autumn 2015 England re-
placed the meningococcus C conjugate vaccine in 
the national vaccination programme for young adults 
with the ACWY conjugate vaccine that provides 
broader protection. Regardless of the cases diag-
nosed, meningococcus W is still very rare in Fin-
land.  
In sporadic cases of meningococcus infection, all 
persons in close contact with the patient – except for 
health care personnel – should be given prophylactic 
medication and a vaccination, if infection with the 
strain in question can be prevented by vaccination. 
Finland has vaccines against the meningococcus 
serotype groups A, C, W and Y. The Defence Forces 
are administering a quadrivalent polysaccharide 
vaccination to all recruits, but infections belonging 
to serogroup B are still being found among them, 
since the vaccine affords no protection from it.  No 
meningococcus infections were diagnosed in the 
Defence Forces in 2015. Conjugated meningococcus 
vaccines are mainly used in connection with epidem-
ics and travel. New vaccines against group B menin-
gococcus strains have entered the market, but are not 
yet used in Finland. 
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Table 17. Meningococcal infections by serogroup, 2006–2015 (no. of cases).  
 A B C W Y Unknown Total 
2006 0 38 5 0 1 1 45 
2007 0 29 8 0 5 0 42 
2008 0 18 8 0 1 1 28 
2009 0 24 3 0 5 1 33 
2010 0 14 4 1 13 2 34 
2011 0 19 6 1 7 1 34 
2012 0 17 3 1 8 4 33 
2013 0 10 2 0 8 0 20 
2014 0 7 5 1 5 3 21 
2015 0 8 5 4 3 2 22 
 
 
MMR DISEASES (MEASLES,  
MUMPS, RUBELLA) 
In 2015, the occurrence of diseases prevented by the 
MMR vaccine was similar to previous years in Fin-
land, with the exception of rubella, of which a few 
more cases were diagnosed than in recent years. 
Two cases of measles were diagnosed. One of the 
patients was a foreign-born adult, who had arrived in 
Finland a while before the outbreak of the disease. 
The other patient was an unvaccinated 1-year-old 
child born in Finland. In this case, the source of 
infection remained unknown. 
Mumps was diagnosed in two individuals, both in-
fected abroad. One of the patients was a male of 
foreign origin, whose vaccination coverage is un-
known and the other was a male born in Finland. His 
series of MMR vaccinations had not been complet-
ed. 
Five laboratory findings of rubella were reported 
(2014: 0, 2013: 3). Congenital rubella syndrome 
(CRS) was diagnosed in one newborn, whose moth-
er had contracted a disease abroad during pregnancy, 
with symptoms similar to rubella. The other four 
findings were detected in adults in the same work-
place, who were born before the introduction of 
large-scale MMR vaccinations, and were therefore 
most probably unvaccinated. 
VARICELLA VIRUS 
The number of varicella findings reported to the 
National Infectious Diseases Register was 505 in 
2015, which corresponds to the level of the two 
previous years (2013: 455, 2014: 476). Of these 
findings, 208 were diagnosed by antigen detection, 
160 by nucleic acid detection, 165 by serological 
diagnostics and one by direct microscopy. There 
were 36 (7.1%) reports based on a diagnosis from 
cerebrospinal fluid, involving the identification of 
nucleic acid in 32 cases, antibodies in eight and 
antigen in two cases. 
Virus findings were reported among all age groups, 
the youngest being one month and the oldest 94 
years old. Childhood varicella or chicken pox is a 
very common disease, with an estimated 57,000 
cases in Finland every year. In most cases, it is diag-
nosed on the basis of symptoms and does not result 
ina laboratory sample being taken. In contrast, her-
pes zoster, or shingles, caused by the varicella virus 
being reactivated, is common, particularly in the 
elderly and requires the use of health care services, 
which can be seen in the age distribution of the virus 
findings. The incidence of varicella virus amongst 
the entire population was 9.2/100,000 on average, 
but in the 70 to 74 age group it is 10.1/100,000 and 
14.9/100,000 in the age group of 75 and over. 
Varicella vaccination is currently recommended for 
persons in close contact with immunocompromised 
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individuals and everyone aged 13 or over who has 
not had the chicken pox. A vaccine for herpes zoster, 
which prevents the later reactivation of the varicella 
virus, became available on the market in 2015. 
BORRELIA (LYME DISEASE) 
In 2015, the number of reported cases of borrelia 
totalled 1,912, an all-time record. Of these reports, 
37 were based on nucleic acid detection and 1,899 
on a serological test. Cases were reported in all parts 
of the country. The average incidence was 
35/100,000, but there was considerable regional 
variation. As in previous years, the incidence was 
highest in the Åland (1,981/100,000), the 573 cases 
diagnosed there accounting for almost a third of all 
cases of Borrelia in Finland. As before, the frequen-
cy of borrelia was highest in the autumn, the majori-
ty of cases occurring from August to October. The 
majority of cases (76%) were diagnosed in patients 
aged 45 and over. No differences between gender 
were diagnosed. 
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Figure 20. Incidence of Borrelia (cases/100,000 population) by hospital district, 2015. 
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TICK-BORNE ENCEPHALITIS (TBE) 
In 2015, a record number of TBE antibody findings 
were reported to the National Infectious Diseases 
Register, 67. Positive findings were diagnosed in 
April‒November, mainly in August. Patients who 
contracted TBE were aged between 5 and 87 (aver-
age age 49) and two of them died. 
In order to identify the place of acquisition, the Na-
tional Institute for Health and Welfare interviewed 
patients who had been diagnosed with TBE and/or 
studied their patient records. Fourteen patients con-
tracted TBE on Åland, 50 in mainland Finland and, 
in the case of three individuals, the place of infection 
remained unclear. All residents of Åland have been 
entitled to a TBE vaccination free of charge since 
2006.  
In mainland Finland, most TBE infections were 
contracted in known risk areas: the Turku archipela-
go (18), of which twelve occurred in Parainen; the 
Lappeenranta region (7), of which four occurred in 
the Sammonlahti area; the Kemi region (3); the 
Kotka archipelago (8) and the Kuopio region (2, a 
new place of acquisition being Kaavi). Other places 
of infection included Inkoo, Espoo, Raseborg and 
Pyhäjoki. Porkkala, Oulu, Ilomantsi, Muurame, the 
Rauma archipelago and Vierumäki  emerged as new 
potential areas of infection, as a single infection was 
diagnosed in each of them.  
The TBE virus was identified in ticks not only on 
Åland, but also in the Turku archipelago and the 
Lappeenranta region decades ago, and in collections 
performed in the following risk areas in recent years: 
Isosaari in Helsinki, the Kokkola archipelago and 
Maksniemi in Simo. 
If a patient falls ill with meningitis or encephalitis 
between May and November, even if he or she has 
not noticed a tick bite TBE should be suspected, 
especially if the case occurs in a known high-risk 
area. Because new endemic TBE regions may con-
tinue to emerge, the possibility of TBE infection 
should be considered even beyond currently known 
risk areas. 
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Figure 21. Cases of TBE by location of acquisition, 2015, and TBE virus findings in ticks, 1996–2015. 
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PUUMALA VIRUS 
In 2015, a total of 1,463 cases of Puumala virus in-
fection were reported (26.8/100,000), less than in 
2014 (2,087). The incidence of the virus varies de-
pending on the virus reservoir, i.e. the size of the 
bank vole population, following a three or four year 
cycle, in accordance with the geographical region. 
The previous peaks occurred in 2005, 2008, 2011 and 
2014. Of the patients, 60% were men and most pa-
tients were of working age. 31 (2.1%) cases occurred 
in patients under 20 years of age. The incidence was 
highest in the Kainuu (133/100,000) and Central 
Ostrobothnia hospital district (85/100,000). 
THL – Report 15/2016 
 
 Infectious Diseases in Finland  2015  
 
 60    
 
 
Figure 22. Incidence of Puumala virus (cases/100,000 population) by hospital district, 2015.  
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POGOSTA DISEASE (SINDBIS VIRUS) 
In 2015, 15 cases of Pogosta disease, confirmed with 
antibody testing, were diagnosed in Finland, which 
was the lowest on record during the register-based 
monitoring of the disease and considerably less than 
last year (32). The incidence was highest in the 
North Ostrobothnia Hospital District (1.2/100,000). 
Only one case was confirmed in the North Karelia 
Hospital District, historically a high incidence area. 
Of the patients, all were of working age (15–64), 
73% were women and 60% of the cases were diag-
nosed in August–September. 
Since 1974, Pogosta disease has followed a regular 
seven-year cycle, except in 2009. The epidemic 
peaked in 1981, 1995 and 2002; in 2009, however, 
only 106 cases were reported (2/100,000). 
TULAREMIA (FRANCISELLA  
TULARENSIS) 
In 2015, the number of tularemia cases reported, 104 
(incidence 1.9/100,000), was significantly higher 
than in 2014 (n=9) or 2013 (n=15), but fewer than in 
the peak years in the past. Most cases (82/104) were 
diagnosed in August–September and the other re-
ports were submitted individually in different 
months. The annual incidence of tularemia varies 
considerably (between 0.2 and 18/100,000) and local 
epidemics break out every few years, particularly in 
the regions of Ostrobothnia and Central Finland. 
RABIES 
Doctors are required to report cases where risk as-
sessment after exposure has led to the administration 
of a course of rabies vaccinations and, possibly, 
rabies immunoglobulin treatment. In 2015, 40 re-
ports were made, fewer than in 2014 (53).  
The number of patients who had been exposed while 
travelling abroadwas 32 (78 %): 11 in Thailand, two 
in Indonesia, two in the Philippines, two in India and 
two in Russia. Others were individual cases of expo-
sure in different countries.  
More than half (19/32) of the cases of exposure 
abroad were related to a dog bite, six to a monkey 
bite and the others to contacts with cats, bats or 
hedgehogs. 
Eight cases of exposure in Finland were reported, 
four related to bats and the others to contacts with a 
cat, dog, bear or weasel. No cases of exposure to 
rabies bait vaccine were reported in 2015. 
DIPHTHERIA (CORYNEBACTERIUM 
DIPHTHERIAE) 
One case of diphtheria was diagnosed in 2015 in an 
unvaccinated asylum seeker, who arrived from Swe-
den and came originally from Afghanistan. The 
latest diagnosed case of diphtheria in Finland was in 
2001. 
RELAPSING FEVER (BORRELIA  
RECURRENTIS) 
In 2015, two individuals were diagnosed with re-
lapsing fever caused by the bacterium Borrelia re-
currentis. Both persons were asylum seekers, origi-
nally from Africa.  
TRAVEL-RELATED INFECTIONS 
Malaria 
Malaria was diagnosed in 38 patients in Finland in 
2015. There were 31 cases of Plasmodium falcipa-
rum, plus one P. falciparum and P. vivax double 
infection, one P. vivax, four cases of P. ovale and 
one P. malariae infection. All malaria cases origi-
nated in Africa. Of the patients, 18 (47%) were im-
migrants from a malaria area who had returned to 
visit their former home region; 10 (26%) were im-
migrants who had fallen ill immediately after arriv-
ing in Finland, and three were visitors to Finland. 
Five of the patients were native Finns who had taken 
a trip of less than six months to a malaria region, and 
two were Finns residing in a malaria region. None of 
the patients who fell ill had used the appropriate 
prophylaxis. One person born in Europe died from 
P. falciparum malaria, not having sought treatment 
after the symptoms appeared. The only symptom in 
two African women diagnosed with malaria caused 
by P. falciparum was severe anaemia during preg-
nancy. 
 
THL – Report 15/2016 
 
 Infectious Diseases in Finland  2015  
 
 62    
 
Table 18. Malaria cases in Finland in 2015 by 
country of acquisition. 
Continent Country Cases 
Africa Burkina Faso 1 
 Eritrea 1 
 South Sudan 4 
 Ethiopia 1 
 Ghana 5 
 Cameroon 8 
 Kenya 3 
 Central African Republic 1 
 Democratic Republic of the Kongo 1 
 Nigeria 3 
 Rwanda 1 
 Zambia 2 
 Sierra Leone 1 
 Somalia 4 
 Uganda 2 
 Total 38 
 
Dengue fever  
The annual number of dengue fever infections has 
varied between 35 and 90. In 2015, laboratories 
reported 54 findings; the majority of which (47/54) 
occurred in the age group 15 to 59. Diagnoses were 
made at all times of the year. Of the infections, 22 
were reported as having been contracted in Asia 
(Thailand 11, Indonesia 6, India 2, the Philippines 2, 
the Maldives 1), one in Australia and one in South 
America (Brazil). Information on the country of 
acquisition is not available in all cases. 
Chikungunya 
In 2015, laboratories reported seven findings of 
Chikungunya. In the previous year, there were four 
cases. In 2015, approximately 650,000 infections 
caused by the chikungunya virus were reported in 
the Caribbean and Americas, clearly fewer than in 
2014. Outbreaks of minor epidemics were also re-
ported in the Pacific islands. Information on the 
country of acquisition is not available in all cases. 
OTHER TRAVEL-RELATED 
INFECTIONS 
A significant percentage of the following infections 
are travel-related:  legionella, salmonella, campylo-
bacter, shigella, EHEC, hepatitis A, hepatitis B, 
gonorrhoea, syphilis, HIV and AIDS, carbapenem-
resistant gram-negative bacilli, MMR diseases and 
exposure to rabies. Data on the country of acquisi-
tion and means of transmission is discussed sepa-
rately for each of these diseases in the respective 
section of this report. 
BLOOD AND CEREBROSPINAL FLUID 
FINDINGS IN CHILDREN 
Blood culture findings in children 
In 2014, 461 cases of bacterial findings were diag-
nosed in blood cultures from children under 15 years 
of age. In comparison with previous years, the num-
ber has remained largely unchanged (in 2006–2014, 
562 on average, variation 439–681). 
Approximately one half of the findings (233 out of 
461) were in babies under 12 months of age. Among 
infants, Staphylococcus epidermidis and other coag-
ulase-negative staphylococci caused 36% of blood 
culture positive infections (table 19). Although these 
bacteria belong to normal skin flora, they typically 
cause treatment-related late-onset sepsis in newborn 
babies in intensive care. Streptococcus agalactiae 
(Group B streptococcus, GBS), typically contracted 
from the mother’s birth canal during labour and 
causing an infection (early-onset sepsis) in the new-
born baby during its first days of life, caused 11% of 
the findings. Other common causes of infection were 
Escherichia coli (16% of the findings), Staphylococ-
cus aureus (12%), Enterococcus faecalis (4%) and 
Streptococcus pneumoniae (3%). 
In the age group of 1 to 14 years, S. aureus (24%) 
was the most common cause of blood culture posi-
tive infections in 2015 (table 20). The number of S. 
pneumoniae findings decreased quickly after the 
introduction of a pneumococcus vaccination to the 
national vaccination programme in 2010 and, in 
recent years, the figure has been less than half of the 
preceding level, at 15% in 2015. Other findings in 
this age group were coagulase-negative staphylococ-
ci (21%), E. coli (9%), Streptococcus pyogenes (6%) 
and the Streptococcus viridans group (3%). 
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Fungal findings are rare in children's blood cultures, 
but in 2015, Candida albicans was diagnosed in the 
blood culture samples of three children aged 0–2 
years. 
Cerebrospinal fluid findings in children 
The number of cerebrospinal fluid findings related to 
children’s central nervous system infections re-
mained on a par with previous years, as did the dis-
tribution of pathogens. The total number of cases 
reported in 2015 was 30 (the annual average from 
2006 to 2014 was 30, variation 22–37), of which six 
were diagnosed in under 12 month old infants. 
Bacteria found in the under 12 month age group 
included S. agalactiae, E. coli and S. aureus (table 
21), and in the age group 1 to 14 years, Neisseria 
meningitidis, S. pneumoniae, staphylococci and 
Enterococcus faecalis (table 22). There were no 
fungal findings in cerebrospinal fluid samples. 
 
GBS in newborns 
Between 1995 and 2014, an average of 31 cases per 
year of early-onset GBS in newborns (diagnosed 
from blood and/or cerebrospinal fluid in children 
under the age of 7 days) were reported; the variation 
was 17 to 57 cases per year, and the incidence was 
0.3 to 1.0 per 1,000 live births. In 2015, the number 
of cases was the lowest on record at only 13 
(0.2/1000 live births). This is probably due to im-
proved preventive practices. The majority of early-
onset GBS cases can be prevented by administering 
an antimicrobial prophylaxis to mothers whose GBS 
colonisation puts the newborn at risk of a GBS in-
fection. An average of 15 annual cases of late GBS 
disease cases detected at the age of more than 7 days 
have occurred during the fifteen-year surveillance 
period (range 6–24; incidence 0.1–0.4 cases per 
1,000 live births). There were 11 cases in 2015 (0.2 
cases per 1,000 live births). Antimicrobial prophy-
laxis during labour does not prevent early-onset 
GBS in newborns. 
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Table 19. Blood culture findings in infants (under 12 months), 2006–2015 (no. of cases). 
 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Staphylococcus epidermidis 100 92 87 64 70 75 50 62 46 49 
Escherichia coli 44 42 38 37 45 48 25 41 37 38 
Staphylococcus, other  
coagulase-negative 42 43 33 43 32 35 26 33 45 34 
Staphylococcus aureus 37 25 23 22 24 21 31 22 20 28 
Streptococcus agalactiae 55 51 49 51 54 42 36 33 31 26 
Enterococcus faecalis 22 8 5 10 20 12 15 16 9 10 
Streptococcus viridans  
group 9 9 8 9 17 13 6 8 8 9 
Enterobacter species 13 8 6 3 3 10 5 4 2 7 
Streptococcus pneumoniae 27 21 26 25 20 11 8 8 6 6 
Bacillus 1 4 4 2 1 1 1 1 1 5 
Serratia species 2 3 4 1 2 4 0 1 0 4 
Pseudomonas aeruginosa 0 0 2 0 2 1 0 0 0 3 
Klebsiella species 8 6 7 9 3 7 6 6 4 3 
Streptococcus, other beta-
haemolytic 3 0 0 4 2 0 1 1 1 1 
Neisseria meningitidis 2 3 3 5 4 1 2 4 3 1 
Haemophilus influenzae 1 1 2 2 1 0 4 1 2 1 
Bacteroides, other than 
fragilis group 0 0 0 0 0 0 0 0 0 1 
Yersinia enterocolitica 0 0 0 0 0 0 0 0 1 1 
Salmonella, other than 
Typhi or Paratyphi 0 0 0 1 0 0 0 1 1 1 
Streptococcus pyogenes 0 3 2 4 2 0 6 1 2 0 
Streptococcus milleri  
group 1 0 0 0 0 0 0 0 0 0 
Streptococcus bovis group 0 0 0 2 0 0 0 0 0 0 
Enterococcus, other or 
unidentified 0 0 0 2 0 0 1 0 0 0 
Enterococcus faecium 3 0 1 1 2 1 2 1 1 0 
Propionibacterium species 0 1 0 0 0 1 0 0 0 0 
Mycobacterium species 0 0 0 0 0 0 0 0 0 0 
Listeria monocytogenes 2 1 0 1 2 0 1 1 1 0 
Clostridium, other than 
perfringens 1 0 0 0 0 0 1 0 0 0 
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 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Peptostreptococcus and 
Peptococcus 0 0 0 0 1 0 0 0 0 0 
Stenotrophomonas  
maltophilia 0 2 0 2 2 0 0 0 0 0 
Haemophilus, other than 
influenzae 1 0 1 0 0 1 0 0 0 0 
Acinetobacter 3 2 1 1 3 2 1 2 0 0 
Veillonella species 1 0 0 0 0 0 0 0 0 0 
Prevotella species 0 0 1 0 0 0 0 0 0 0 
Bacteroides fragilis group 0 1 1 0 1 0 0 0 0 0 
Pseudomonas, other than 
aeruginosa 0 0 0 0 0 0 0 0 1 0 
Proteus mirabilis 1 1 0 0 0 0 0 0 0 0 
Citrobacter species 1 0 0 1 1 0 1 0 0 0 
Other bacteria 8 7 7 5 5 9 8 3 6 5 
Total 388 334 311 307 319 295 237 250 228 233 
Candida albicans 4 2 3 1 2 1 1 2 3 2 
Other candida species 0 2 1 0 0 1 2 0 1 0 
Total 4 4 4 1 2 2 3 2 4 2 
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Table 20. Blood culture findings in children (aged 1 to 14), 2006–2015 (no. of cases). 
 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Staphylococcus aureus 37 42 40 36 43 42 47 48 40 54 
Streptococcus pneumoniae 100 115 87 92 95 74 35 35 32 27 
Staphylococcus epidermidis 40 33 22 31 37 29 17 25 28 26 
Staphylococcus, other  
coagulase-negative 8 19 13 17 21 13 11 9 19 23 
Escherichia coli 16 12 14 12 15 11 14 9 17 20 
Streptococcus pyogenes 9 13 11 11 6 15 9 8 14 13 
Streptococcus viridans  
group 25 21 21 25 37 23 27 27 14 10 
Bacillus 6 0 6 3 3 2 5 5 4 6 
Enterobacter species 1 2 4 3 2 3 1 0 0 6 
Streptococcus, other beta-
haemolytic 3 4 0 2 3 1 1 1 1 4 
Enterococcus faecalis 2 6 6 4 6 3 5 1 1 3 
Acinetobacter 1 2 2 4 1 0 1 3 1 3 
Streptococcus milleri  
group 2 0 2 2 2 1 1 0 2 2 
Streptococcus bovis group 1 0 0 0 0 0 0 0 0 1 
Mycobacterium species 0 0 0 0 0 1 0 0 0 1 
Peptostreptococcus and 
Peptococcus 0 0 0 0 0 2 1 0 0 1 
Neisseria meningitidis 5 3 4 0 6 2 2 3 1 1 
Haemophilus, other than 
influenzae 1 0 0 0 0 0 1 1 0 1 
Haemophilus influenzae 1 2 3 3 2 5 0 3 5 1 
Bacteroides fragilis group 0 0 0 1 0 2 0 0 1 1 
Pseudomonas, other than 
aeruginosa 0 1 0 3 0 0 0 0 0 1 
Pseudomonas aeruginosa 3 2 1 3 7 4 3 4 9 1 
Salmonella, other than 
Typhi or Paratyphi 2 5 2 0 6 2 3 4 1 1 
Klebsiella species 3 6 5 2 4 2 6 3 0 1 
Streptococcus agalactiae 0 2 1 0 0 0 0 0 0 0 
Enterococcus, other or 
unidentified 2 2 3 0 1 0 0 1 0 0 
Enterococcus faecium 3 4 2 5 7 0 2 2 1 0 
Propionibacterium species 0 0 0 0 0 0 2 1 0 0 
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 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Listeria monocytogenes 0 0 0 0 0 0 0 1 0 0 
Corynebacterium  
diphteriae 0 0 0 0 0 0 0 0 1 0 
Clostridium, other than 
perfringens 0 1 1 1 4 4 1 1 2 0 
Clostridium perfringens 1 2 0 1 1 0 0 0 0 0 
Stenotrophomonas  
maltophilia 1 3 4 2 2 0 1 1 1 0 
Veillonella species 1 0 0 0 1 0 0 0 0 0 
Fusobacterium species 3 5 5 1 1 1 1 1 1 0 
Serratia species 2 1 0 0 1 0 0 1 0 0 
Salmonella Typhi 0 2 0 0 0 2 0 1 0 0 
Proteus mirabilis 0 1 0 0 0 0 0 0 0 0 
Citrobacter species 0 2 2 1 1 0 0 0 3 0 
Other bacteria 14 15 10 13 24 11 14 9 12 20 
Total 293 328 271 278 339 255 211 208 211 228 
Candida albicans 1 0 2 0 2 0 1 2 1 1 
Other candida species 3 3 1 0 0 3 0 1 0 1 
Total 4 3 3 0 2 3 1 3 1 2 
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Table 21. Cerebrospinal fluid culture findings in infants (under 12 months), 2006–2015 (no. of cases). 
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Streptococcus agalactiae 8 8 3 6 10 3 4 1 7 3 
Escherichia coli 2 1 1 1 2 1 0 0 2 2 
Staphylococcus aureus 0 1 2 2 1 0 3 2 1 1 
Streptococcus viridans  
group 0 0 0 2 0 1 0 0 0 0 
Streptococcus pyogenes 0 0 0 1 0 0 0 0 0 0 
Streptococcus pneumoniae 1 4 3 2 3 2 1 2 2 0 
Enterococcus faecium 1 0 0 0 0 0 0 0 0 0 
Enterococcus faecalis 2 1 0 0 0 0 0 0 0 0 
Staphylococcus, other  
coagulase-negative 0 0 4 1 0 0 2 0 0 0 
Staphylococcus epidermidis 3 2 1 2 2 2 1 3 2 0 
Propionibacterium species 0 0 0 0 0 0 0 0 1 0 
Mycobacterium species 0 0 0 0 1 0 0 0 0 0 
Bacillus 1 0 0 0 0 0 0 0 1 0 
Neisseria meningitidis 1 2 1 2 1 0 3 3 2 0 
Haemophilus influenzae 0 0 0 1 0 0 0 0 1 0 
Acinetobacter 1 0 0 0 0 0 0 0 0 0 
Bacteroides, other than 
fragilis group 0 1 0 0 0 0 0 0 0 0 
Klebsiella species 0 0 0 1 0 0 1 0 0 0 
Citrobacter species 0 1 0 0 1 0 0 0 1 0 
Other bacteria 0 0 0 1 0 0 0 1 1 0 
Total 20 21 15 22 21 9 15 12 21 6 
Candida albicans 0 0 0 1 0 0 0 0 0 0 
Total 0 0 0 1 0 0 0 0 0 0 
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Table 22. Cerebrospinal fluid culture findings in children (aged 1 to 14), 2006–2015 (no. of cases). 
 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Staphylococcus epidermidis 0 1 5 2 1 2 1 0 3 3 
Streptococcus viridans  
group 2 0 0 0 0 0 0 0 0 2 
Propionibacterium species 0 0 0 0 0 1 0 0 1 2 
Neisseria meningitidis 7 6 3 2 3 4 2 3 1 2 
Streptococcus pneumoniae 5 5 2 4 2 3 0 4 2 1 
Enterococcus faecalis 0 0 0 0 1 0 0 0 0 1 
Staphylococcus, other  
coagulase-negative 0 0 0 1 0 0 0 1 0 1 
Staphylococcus aureus 0 2 3 3 2 2 2 1 0 1 
Streptococcus, other beta-
haemolytic 0 0 0 1 0 0 0 0 0 0 
Peptostreptococcus and 
Peptococcus 1 0 0 0 0 0 0 0 0 0 
Haemophilus influenzae 0 0 0 0 0 1 0 0 1 0 
Bacteroides fragilis group 1 0 0 0 0 0 0 0 0 0 
Enterobacter species 0 0 0 1 0 0 1 0 0 0 
Other bacteria  0 0 2 1 1 0 0 1 1 1 
Total 17 14 15 15 10 13 8 10 9 14 
 
 
BLOOD AND CEREBROSPINAL FLUID 
FINDINGS IN ADULTS 
Blood culture findings in adults 
In 2015, the total number of bacterial findings in 
adults' blood culture samples was 14,599. The num-
ber of findings has increased continuously, particu-
larly the percentage diagnosed in the over 65 age 
group (68%, 9,917/14,599). Gram-positive bacteria 
were more common in the working-age population 
(aged 15 to 64) and gram-negative bacteria among 
those aged 65 or more. The number of fungi in 
adults' blood cultures was on a par with previous 
years, totalling 216 findings. 
In both the working-age population (24% of all find-
ings) and the over 65 age group (34%), the most 
common bacterial finding in blood was Escherichia 
coli. Other common bacterial findings included (ta-
bles 24 and 25) Staphylococcus aureus (working age 
17%, over 65s 12%), coagulase-negative staphylo-
cocci (working age 10%, over 65 8%), Streptococ-
cus pneumoniae (working age 7%, over 65s 4%) and 
Klebsiella species (working age 4%, over 65s 7%). 
An estimated, one half of the Staphylococcus aureus 
findings were related to treatment, as were almost all 
of the coagulase-negative staphylococci.  Anaerobic 
bacteria constituted around 4% of all blood culture 
positive findings among adults. 
Cerebrospinal fluid findings in adults 
In 2015, the total number of microbial findings in 
adults' cerebrospinal fluid was 142, which corre-
sponds to the 2006–2014 average. Patients over the 
age of 65 accounted for 30% of cases. 
In the working-age population, coagulase-negative 
staphylococci accounted for 31% of the findings 
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(table 26). The most common actual pathogens were 
S. pneumoniae (17%) and S. aureus (14%). In pa-
tients aged 65 years or older, the most common find-
ings were S. pneumoniae (29%), Listeria monocyto-
genes (14%), Propionibacterium species (12%),
coagulase-negative staphylococci (12%) and S. au-
reus (10%) (table 27).
Group A streptococcus 
In 2015, the number of invasive infections of Group 
A streptococcus (Streptococcus pyogenes) increased 
slightly in comparison with the previous year (2015: 
178 cf. 2014: 211). The two most prevalent emm 
types, emm28 and emm89, were the same as previ-
ously. In earlier years, the numbers of the common 
emm1 type increased after a decrease in the previous 
year (2015: 19, 11% cf. 2014: 10.5%). The numbers 
of macrolide-resistant type emm33 began to decline 
(2; 1%). In addition to the aforementioned, the per-
centages of emm types emm12 (8; 5%) and emm66 
(6; 3%) have remained the same. Although new 
emm types are continuously emerging, the four most 
common emm types – emm28, emm89, emm1 and 
emm4 – accounted for 74% of all emm types in 
2015. 
Table 23. Group A streptococcus blood findings by emm type, 2006–2015 (no. of cases and %). 
Each emm type includes all variants detected. 
Year Analysed strains emm1 emm28 emm4 emm89 emm33 Others 
2006 162 26 (16%) 33 (20%) 1 (1%) 11 (7%) 0 (0%) 91 (56%) 
2007 205 57 (28%) 26 (13%) 7 (3%) 12 (6%) 0 (0%) 103 (50%) 
2008 218 51 (23%) 46 (21%) 4 (2%) 10 (5%) 0 (0%) 107 (49%) 
2009 191 24 (13%) 56 (29%) 8 (4%) 28 (15%) 0 (0%) 75 (39%)* 
2010 171 22 (13%) 38 (22%) 6 (4%) 24 (14%) 0 (0%) 81 (47%) 
2011 161 24 (15%) 37 (23%) 6 (4%) 30 (19%) 0 (0%) 64 (40%) 
2012 207 22 (11%) 65 (31%) 13 (6%) 58 (28%) 5 (2%) 44 (21%) 
2013 176 18 (10%) 58 (33%) 11 (6%) 43 (24%) 13 (7%) 33 (19%) 
2014 205 10 (5%) 62 (30%) 17 (8%) 47 (23%) 12 (6%) 57 (28%) 
2015 173 19 (11%) 60 (35%) 15 (9%) 33 (19%) 2 (1%) 44 (25%)* 
* One untyped finding in 2009 and 2015.
THL – Report 15/2016  Infectious Diseases in Finland  2015 
71 
Table 24. Blood culture findings in patients aged 15 to 64, 2006–2015 (no. of cases). 
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Escherichia coli 797 837 872 884 931 934 942 951 1070 1113 
Staphylococcus aureus 565 544 526 540 579 641 617 644 800 786 
Streptococcus pneumoniae 348 352 480 440 412 391 363 356 307 350 
Staphylococcus epidermidis 281 265 278 312 263 223 182 210 240 270 
Staphylococcus, other  
coagulase-negative 128 147 156 136 140 144 104 154 191 209 
Klebsiella species 144 157 185 186 207 164 217 220 218 206 
Streptococcus, other  
beta-haemolytic 135 129 128 122 139 154 133 177 173 156 
Streptococcus milleri  
group 63 65 73 56 68 86 79 98 127 128 
Bacteroides fragilis group 85 82 109 68 110 108 103 101 132 125 
Streptococcus agalactiae 76 83 96 95 110 75 89 96 89 113 
Enterococcus faecalis 83 105 83 107 86 97 102 83 99 110 
Streptococcus viridans  
group 130 115 137 144 147 156 150 149 129 108 
Streptococcus pyogenes 105 133 157 116 113 104 126 105 122 99 
Enterobacter species 77 70 69 81 99 86 96 90 85 97 
Pseudomonas aeruginosa 62 72 74 78 91 92 79 91 74 81 
Enterococcus faecium 64 80 91 87 85 101 89 96 103 72 
Bacillus 22 24 25 21 32 34 27 42 60 54 
Serratia species 18 19 24 27 20 32 26 32 31 39 
Fusobacterium species 19 31 31 27 37 32 48 41 47 37 
Peptostreptococcus and 
Peptococcus 18 11 12 27 15 30 18 22 38 36 
Proteus mirabilis 18 14 14 18 26 17 24 22 23 32 
Clostridium, other than 
perfringens 25 18 24 29 23 20 32 29 43 30 
Citrobacter species 27 19 23 29 31 28 25 23 35 30 
Campylobacter species 3 8 7 11 10 4 6 8 33 26 
Salmonella, other than 
Typhi or Paratyphi 47 52 43 23 39 32 32 36 28 25 
Haemophilus influenzae 9 26 18 19 18 22 25 23 18 22 
Stenotrophomonas  
maltophilia 7 5 15 12 12 9 7 14 16 20 
Acinetobacter 10 21 13 18 14 21 14 11 15 18 
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 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015  
Enterococcus, other or 
unidentified 6 4 7 13 13 12 20 8 5 13 
Morganella morganii 8 7 14 8 6 8 7 18 12 13 
Clostridium perfringens 11 12 10 16 15 8 11 8 13 12 
Neisseria meningitidis 20 21 9 13 14 17 12 5 10 12 
Capnocytophaga  
canimorsus 8 8 8 11 11 17 13 14 15 12 
Pseudomonas, other than 
aeruginosa 0 3 5 6 6 8 8 8 14 11 
Prevotella species 11 8 13 13 15 16 16 10 12 10 
Listeria monocytogenes 10 9 8 9 15 7 17 11 18 9 
Streptococcus bovis group 5 7 1 6 7 6 6 4 5 8 
Propionibacterium species 7 5 3 9 6 9 7 9 11 8 
Haemophilus, other than 
influenzae 3 3 3 0 2 3 10 5 6 8 
Veillonella species 3 4 3 6 5 12 6 8 9 5 
Bacteroides, other than 
fragilis group 4 3 5 10 1 7 3 7 8 5 
Proteus vulgaris 7 3 2 3 2 2 3 2 4 4 
Mycobacterium species 4 5 2 2 2 4 3 8 3 3 
Yersinia enterocolitica 0 1 0 1 1 0 0 0 0 2 
Salmonella Paratyphi 3 6 6 3 3 1 3 1 2 2 
Hafnia alvei 0 1 3 6 2 2 2 1 2 2 
Salmonella Typhi 3 4 1 3 9 2 1 5 5 1 
Corynebacterium  
diphteriae 0 0 0 0 0 0 0 0 0 0 
Yersinia pseudotuberculosis 0 0 1 0 0 0 1 1 1 0 
Other bacteria 92 78 94 107 92 99 111 130 156 150 
Total 3,571 3,676 3,961 3,958 4,084 4,077 4,015 4,187 4,657 4,682 
Other candida species 22 26 41 29 37 34 31 45 44 50 
Candida albicans 54 54 55 55 57 74 56 64 53 47 
Other fungi 2 4 2 3 1 3 2 3 3 1 
Total 78 84 98 87 95 111 89 112 100 98 
 
THL – Report 15/2016 
 
 Infectious Diseases in Finland  2015  
 
 73    
 
Table 25. Blood culture findings in patients aged 65 or over, 2006–2015 (no. of cases). 
 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Escherichia coli 1,706 1,759 1,887 2,053 2,230 2,478 2,482 2,875 3,242 3,361 
Staphylococcus aureus 601 568 671 691 728 780 797 876 1,065 1,184 
Klebsiella species 326 339 375 462 469 471 537 556 664 729 
Streptococcus, other beta- 
haemolytic 190 180 193 232 279 285 308 335 442 466 
Streptococcus pneumoniae 270 290 326 294 303 295 342 319 355 426 
Staphylococcus epidermidis 264 275 299 271 326 316 300 343 366 394 
Staphylococcus, other  
coagulase-negative 132 144 171 161 149 162 170 252 293 367 
Enterococcus faecalis 202 219 217 222 229 274 286 301 349 334 
Bacteroides fragilis group 119 135 146 163 178 202 183 201 253 295 
Pseudomonas aeruginosa 154 188 191 184 218 196 250 230 233 253 
Enterobacter species 95 104 131 128 156 156 174 188 172 217 
Enterococcus faecium 100 132 126 170 161 174 169 209 236 204 
Streptococcus viridans  
group 110 113 140 135 132 168 175 191 161 162 
Streptococcus agalactiae 81 77 93 104 126 113 117 129 170 162 
Proteus mirabilis 68 92 99 102 106 97 130 116 156 150 
Streptococcus milleri  
group 67 54 53 62 59 59 65 92 127 144 
Citrobacter species 42 35 65 59 76 59 95 99 97 113 
Serratia species 27 33 50 37 59 56 64 81 72 89 
Streptococcus pyogenes 48 58 50 60 50 48 75 67 73 74 
Clostridium, other than 
perfringens 30 33 30 38 44 38 45 39 60 69 
Clostridium perfringens 36 39 34 49 40 51 56 34 57 61 
Peptostreptococcus and 
Peptococcus 22 25 14 29 36 26 24 32 44 42 
Morganella morganii 14 26 11 18 29 30 16 30 39 40 
Enterococcus, other or 
unidentified 19 15 24 20 25 33 34 17 21 33 
Listeria monocytogenes 25 26 26 20 45 30 36 45 43 32 
Haemophilus influenzae 21 25 21 22 19 37 51 20 32 28 
Acinetobacter 18 11 12 16 16 17 19 21 16 28 
Fusobacterium species 9 15 10 8 17 14 19 18 22 26 
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 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Streptococcus bovis group 17 17 15 25 14 13 21 29 19 22 
Campylobacter species 5 3 5 6 2 1 4 4 13 20 
Propionibacterium species 9 4 5 9 10 13 6 7 12 18 
Prevotella species 10 8 11 15 13 13 7 11 16 18 
Stenotrophomonas  
maltophilia 10 8 3 6 7 4 8 12 7 16 
Proteus vulgaris 9 9 4 4 8 8 12 14 16 15 
Pseudomonas, other than 
aeruginosa 9 9 11 10 10 8 11 12 18 13 
Bacillus 17 9 11 12 7 13 7 17 24 12 
Bacteroides, other than 
fragilis group 3 5 8 13 8 8 16 12 10 11 
Capnocytophaga  
canimorsus 4 2 3 2 2 6 7 12 9 9 
Hafnia alvei 3 6 8 7 6 1 8 6 4 7 
Haemophilus, other than 
influenzae 2 1 1 1 1 0 3 8 4 5 
Mycobacterium species 5 1 4 0 5 1 1 1 2 4 
Veillonella species 2 5 9 5 2 5 5 10 10 4 
Neisseria meningitidis 5 2 6 6 6 6 5 4 2 3 
Salmonella, other than 
Typhi or Paratyphi 11 8 19 6 8 7 13 9 14 3 
Salmonella Paratyphi 0 0 0 0 0 0 0 0 0 1 
Corynebacterium  
diphteriae 0 0 0 0 0 0 0 0 0 0 
Yersinia pseudotuberculosis 1 1 0 3 1 0 1 0 0 0 
Yersinia enterocolitica 1 1 0 1 1 0 3 0 0 0 
Salmonella Typhi 0 0 0 0 0 0 0 0 0 0 
Other bacteria 87 81 119 121 115 134 142 186 234 254 
Total 5,006 5,190 5,707 6,062 6,531 6,906 7,299 8,070 9,274 9,918 
Candida albicans 54 56 66 49 93 65 70 77 72 71 
Other candida species 21 26 26 42 31 47 39 60 44 45 
Other fungi 5 7 8 3 3 4 1 3 0 2 
Total 80 89 100 94 127 116 110 140 116 118 
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Table 26. Cerebrospinal fluid culture findings in patients aged 15 to 64, 2006–2015 (no. of cases). 
 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Staphylococcus epidermidis 32 17 26 18 11 10 21 12 17 20 
Streptococcus pneumoniae 17 13 27 20 15 12 19 13 11 17 
Staphylococcus aureus 9 16 13 13 12 20 15 11 9 14 
Propionibacterium species 5 5 4 4 7 4 5 6 13 12 
Staphylococcus, other  
coagulase-negative 12 7 14 11 8 6 7 12 9 11 
Streptococcus agalactiae 1 5 2 0 2 0 1 1 1 4 
Neisseria meningitidis 20 16 4 9 6 7 6 1 1 3 
Listeria monocytogenes 2 1 1 2 1 1 1 2 2 3 
Acinetobacter 3 5 2 3 0 2 2 0 1 2 
Enterococcus faecalis 4 5 4 3 4 3 3 0 0 2 
Serratia species 0 3 0 0 0 1 0 0 0 1 
Pseudomonas aeruginosa 6 3 4 5 3 1 4 1 2 1 
Mycobacterium species 0 1 2 0 0 1 2 0 0 1 
Enterobacter species 2 2 9 3 1 2 4 2 2 1 
Citrobacter species 0 1 0 0 1 0 1 0 0 1 
Bacillus 6 4 3 0 0 0 2 0 0 1 
Haemophilus, other than 
influenzae 0 1 0 0 0 2 0 0 0 1 
Streptococcus, other beta-
haemolytic 0 0 1 2 1 2 1 0 1 0 
Streptococcus viridans  
group 7 2 1 2 2 4 2 2 2 0 
Streptococcus pyogenes 1 0 2 2 1 1 0 0 2 0 
Streptococcus milleri  
group 0 0 1 0 0 0 0 0 1 0 
Streptococcus bovis group 0 0 0 0 1 0 0 0 0 0 
Stenotrophomonas  
maltophilia 0 1 0 0 0 1 0 0 0 0 
Pseudomonas, other than 
aeruginosa 1 0 1 1 0 1 0 0 0 0 
Proteus mirabilis 0 0 0 0 0 1 0 0 0 0 
Peptostreptococcus and  
Peptococcus 0 0 0 1 0 0 0 0 0 0 
Morganella morganii 0 0 0 0 0 0 0 0 1 0 
Klebsiella species 2 1 4 2 1 2 0 1 5 0 
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 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Escherichia coli 4 3 3 4 1 1 2 1 1 0 
Capnocytophaga  
canimorsus 0 0 0 1 0 0 1 0 1 0 
Campylobacter species 0 0 0 0 0 0 0 1 0 0 
Bacteroides, other than  
fragilis group 0 0 0 0 0 0 0 0 1 0 
Salmonella, other than 
Typhi or Paratyphi 0 0 2 0 0 1 0 0 0 0 
Haemophilus influenzae 0 0 3 1 0 2 1 2 3 0 
Enterococcus, other or  
unidentified 1 0 1 0 0 1 0 0 0 0 
Enterococcus faecium 0 1 0 1 0 2 2 1 0 0 
Clostridium, other than  
perfringens 0 0 0 0 0 0 0 0 1 0 
Other bacteria 4 3 2 4 0 1 2 1 5 2 
Total 139 116 136 112 78 92 104 70 92 97 
Other candida species 2 3 0 1 1 0 1 0 1 2 
Candida albicans 0 1 0 0 0 0 1 0 0 1 
Total 2 4 0 1 1 0 2 0 1 3 
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Table 27. Cerebrospinal fluid culture findings in patients aged 65 or over, 2006–2015 (no. of cases). 
 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015  
Streptococcus pneumoniae 10 4 7 10 6 8 4 8 1 12 
Listeria monocytogenes 3 2 2 2 6 4 4 4 4 6 
Propionibacterium species 2 0 2 2 1 1 2 2 9 5 
Staphylococcus aureus 3 2 3 6 5 5 2 10 4 4 
Staphylococcus, other  
coagulase-negative 3 2 4 3 3 1 3 5 6 3 
Escherichia coli 1 0 1 1 1 2 1 1 0 3 
Staphylococcus epidermidis 9 12 10 6 3 4 7 8 8 2 
Streptococcus agalactiae 0 0 0 1 1 0 0 1 1 1 
Mycobacterium species 0 0 1 1 0 1 0 0 1 1 
Bacillus 0 0 1 0 0 2 1 0 0 1 
Serratia species 0 0 0 0 0 0 0 0 0 1 
Citrobacter species 0 0 0 0 0 1 0 1 0 1 
Streptococcus, other  
beta-haemolytic 1 0 0 1 0 0 0 1 0 0 
Streptococcus viridans  
group 1 1 0 3 1 0 3 1 0 0 
Streptococcus pyogenes 0 0 0 0 0 0 0 0 0 0 
Streptococcus milleri  
group 0 0 0 1 0 0 0 0 0 0 
Streptococcus bovis group 0 0 0 1 0 0 0 0 0 0 
Enterococcus, other or  
unidentified 0 0 0 0 1 0 0 0 0 0 
Enterococcus faecium 0 0 0 2 0 0 0 0 0 0 
Enterococcus faecalis 2 3 0 1 0 0 2 0 2 0 
Corynebacterium  
diphteriae 0 0 0 0 0 0 0 0 0 0 
Clostridium, other than  
perfringens 0 0 0 0 0 0 0 0 0 0 
Clostridium perfringens 0 0 0 0 0 0 0 0 0 0 
Peptostreptococcus and  
Peptococcus 0 0 0 0 0 0 1 0 0 0 
Stenotrophomonas  
maltophilia 0 0 0 0 0 0 0 0 0 0 
Neisseria meningitidis 1 0 1 0 2 0 1 1 0 0 
Haemophilus, other than 
influenzae 0 0 0 0 0 0 0 0 0 0 
Haemophilus influenzae 2 2 1 1 0 1 0 0 0 0 
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 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015  
Capnocytophaga  
canimorsus 0 0 0 0 0 0 0 0 0 0 
Campylobacter species 0 0 0 0 0 0 0 0 0 0 
Acinetobacter 1 1 0 0 0 0 0 0 0 0 
Veillonella species 0 0 0 0 0 0 0 0 0 0 
Prevotella species 0 0 0 0 0 0 0 0 0 0 
Fusobacterium species 0 0 0 0 0 0 0 0 0 0 
Bacteroides, other than  
fragilis group 0 0 0 0 0 0 0 0 0 0 
Bacteroides fragilis group 0 0 0 1 0 0 0 0 0 0 
Pseudomonas, other than 
aeruginosa 0 0 0 0 0 0 0 0 0 0 
Pseudomonas aeruginosa 1 0 2 0 0 0 1 2 0 0 
Other enterobacter species 0 0 0 0 0 0 0 0 0 0 
Yersinia pseudotuberculosis 0 0 0 0 0 0 0 0 0 0 
Yersinia enterocolitica 0 0 0 0 0 0 0 0 0 0 
Salmonella, other than 
Typhi or Paratyphi 0 0 0 0 0 0 0 0 0 0 
Salmonella Paratyphi 0 0 0 0 0 0 0 0 0 0 
Salmonella Typhi 0 0 0 0 0 0 0 0 0 0 
Proteus vulgaris 0 0 0 0 0 0 0 0 0 0 
Proteus mirabilis 0 0 1 1 0 0 0 0 0 0 
Morganella morganii 0 0 0 0 0 0 0 0 0 0 
Klebsiella species 0 0 1 1 0 0 0 0 0 0 
Hafnia alvei 0 0 0 0 0 0 0 0 0 0 
Enterobacter species 0 1 0 0 1 1 1 1 0 0 
Other bacteria  0 0 0 0 1 0 0 1 2 2 
Total 40 30 37 45 32 31 33 47 38 42 
Candida albicans 0 0 1 0 0 0 1 0 0 0 
Other candida species 0 0 0 1 0 1 0 0 1 0 
Other fungi 0 0 0 0 0 0 0 0 0 0 
Total 0 0 1 1 0 1 1 0 1 0 
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Table 28. Blood culture findings in all age groups, 2006–2015 (no. of cases). 
 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015  
Escherichia coli 2,563 2,650 2,811 2,986 3,221 3,471 3,463 3,876 4,366 4,532 
Staphylococcus aureus 1,240 1,179 1,260 1,289 1,374 1,484 1,492 1,590 1,925 2,052 
Klebsiella species 481 508 572 659 683 644 766 785 886 939 
Streptococcus pneumoniae 745 778 919 851 830 771 748 718 700 809 
Staphylococcus epidermidis 685 665 686 678 696 643 549 640 680 739 
Staphylococcus, other  
coagulase-negative 310 353 373 357 342 354 311 448 548 633 
Streptococcus, other beta-
haemolytic 331 313 321 360 423 440 443 514 617 627 
Enterococcus faecalis 309 338 311 343 341 386 408 401 458 457 
Bacteroides fragilis group 204 218 256 232 289 312 286 302 386 421 
Pseudomonas aeruginosa 219 262 268 265 318 293 332 325 316 338 
Enterobacter species 186 184 210 215 260 255 276 282 259 327 
Streptococcus agalactiae 212 213 239 250 290 230 242 258 290 301 
Streptococcus viridans  
group 274 258 306 313 333 360 358 375 312 289 
Enterococcus faecium 170 216 220 263 255 276 262 308 341 275 
Streptococcus milleri  
group 133 119 128 120 129 146 145 190 256 274 
Streptococcus pyogenes 162 207 220 189 171 167 216 181 211 186 
Proteus mirabilis 87 108 113 120 132 114 154 138 179 182 
Citrobacter species 70 56 90 90 109 87 121 122 135 143 
Serratia species 49 56 78 65 82 92 90 115 103 132 
Clostridium, other than 
perfringens 56 52 55 68 71 62 79 69 105 99 
Peptostreptococcus and 
Peptococcus 40 36 26 56 52 58 43 54 82 79 
Bacillus 46 37 46 38 43 50 40 65 89 77 
Clostridium perfringens 48 53 44 66 56 59 67 42 70 73 
Fusobacterium species 31 51 46 36 55 47 68 60 70 63 
Morganella morganii 22 33 25 26 35 38 23 48 51 53 
Haemophilus influenzae 32 54 44 46 40 64 80 47 57 52 
Acinetobacter 32 36 28 39 34 40 35 37 32 49 
Enterococcus, other or 
unidentified 27 21 34 35 39 45 55 26 26 46 
THL – Report 15/2016 
 
 Infectious Diseases in Finland  2015  
 
 80    
 
 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015  
Campylobacter species 8 11 12 17 12 5 10 12 46 46 
Listeria monocytogenes 37 36 34 30 62 37 54 58 62 41 
Stenotrophomonas  
maltophilia 18 18 22 22 23 13 16 27 24 36 
Streptococcus bovis group 23 24 16 33 21 19 27 33 24 31 
Salmonella, other than 
Typhi or Paratyphi 60 65 64 30 53 41 48 50 44 30 
Prevotella species 21 16 25 28 28 29 23 21 28 28 
Propionibacterium species 16 10 8 18 16 23 15 17 23 26 
Pseudomonas, other than 
aeruginosa 9 13 16 19 16 16 19 20 33 25 
Capnocytophaga  
canimorsus 12 10 11 13 13 23 20 26 24 21 
Proteus vulgaris 16 12 6 7 10 10 15 16 20 19 
Neisseria meningitidis 32 29 22 24 30 26 21 16 16 17 
Bacteroides, other than 
fragilis group 7 8 13 23 9 15 19 19 18 17 
Haemophilus, other than 
influenzae 7 4 5 1 3 4 14 14 10 14 
Veillonella species 7 9 12 11 8 17 11 18 19 9 
Hafnia alvei 3 7 11 13 8 3 10 7 6 9 
Mycobacterium species 9 6 6 2 7 6 4 9 5 8 
Yersinia enterocolitica 1 2 0 2 2 0 3 0 1 3 
Salmonella Paratyphi 3 6 6 3 3 1 3 1 2 3 
Salmonella Typhi 3 6 1 3 9 4 1 6 5 1 
Corynebacterium  
diphteriae 0 0 0 0 0 0 0 0 1 0 
Yersinia pseudotuberculosis 1 1 1 3 1 0 2 1 1 0 
Other bacteria 201 181 230 246 236 253 275 328 408 429 
Total 9,258 9,528 10,250 10,603 11,273 11,533 11,762 12,715 14,370 15,060 
Candida albicans 113 112 126 105 154 140 128 145 129 121 
Other candida species 46 57 69 71 68 85 72 106 89 96 
Other fungi 7 11 10 6 4 7 3 6 3 3 
Total 166 180 205 182 226 232 203 257 221 220 
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Table 29. Cerebrospinal fluid culture findings in all age groups, 2006–2015 (no. of cases). 
 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Streptococcus pneumoniae 33 26 39 36 26 25 24 27 16 30 
Staphylococcus epidermidis 44 32 42 28 17 18 30 23 30 25 
Staphylococcus aureus 12 21 21 24 20 27 22 24 14 20 
Propionibacterium species 7 5 6 6 8 6 7 8 24 19 
Staphylococcus, other  
coagulase-negative 15 9 22 16 11 7 12 18 15 15 
Listeria monocytogenes 5 3 3 4 7 5 5 6 6 9 
Streptococcus agalactiae 9 13 5 7 13 3 5 3 9 8 
Neisseria meningitidis 29 24 9 13 12 11 12 8 4 5 
Escherichia coli 8 4 5 6 4 4 4 2 3 5 
Enterococcus faecalis 8 9 4 4 5 3 5 0 2 3 
Streptococcus viridans  
group 10 3 1 7 3 5 5 3 2 2 
Mycobacterium species 0 1 3 1 1 2 2 0 1 2 
Bacillus 7 4 4 0 0 2 3 0 1 2 
Acinetobacter 5 6 2 3 0 2 2 0 1 2 
Serratia species 0 3 0 0 0 1 0 0 0 2 
Citrobacter species 0 2 0 0 2 1 1 1 1 2 
Haemophilus, other than 
influenzae 0 1 0 0 0 2 0 0 0 1 
Pseudomonas aeruginosa 7 3 6 5 3 1 5 3 2 1 
Enterobacter species 2 3 9 4 2 3 6 3 2 1 
Streptococcus, other beta-
haemolytic 1 0 1 4 1 2 1 1 1 0 
Streptococcus pyogenes 1 0 2 3 1 1 1 0 2 0 
Streptococcus milleri  
group 0 0 1 1 0 0 0 0 1 0 
Streptococcus bovis group 0 0 0 1 1 0 0 0 0 0 
Enterococcus, other or 
unidentified 1 0 1 0 1 1 0 0 0 0 
Enterococcus faecium 1 1 0 3 0 2 2 1 0 0 
Clostridium, other than 
perfringens 0 0 0 0 0 0 0 0 1 0 
Peptostreptococcus and 
Peptococcus 1 0 0 1 0 0 1 0 0 0 
Stenotrophomonas  
maltophilia 0 1 0 0 0 1 0 0 0 0 
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 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Haemophilus influenzae 2 2 4 3 0 4 1 2 5 0 
Capnocytophaga  
canimorsus 0 0 0 1 0 0 1 0 1 0 
Campylobacter species 0 0 0 0 0 0 0 1 0 0 
Bacteroides, other than 
fragilis group 0 1 0 0 0 0 0 0 1 0 
Bacteroides fragilis group 1 0 0 1 0 0 0 0 0 0 
Pseudomonas, other than 
aeruginosa 1 0 1 1 0 1 0 0 0 0 
Salmonella, other than 
Typhi or Paratyphi 0 0 2 0 0 1 0 0 0 0 
Proteus mirabilis 0 0 1 1 0 1 0 0 0 0 
Morganella morganii 0 0 0 0 0 0 0 0 1 0 
Klebsiella species 2 1 5 4 1 2 1 1 5 0 
Other bacteria 4 3 4 6 2 1 2 4 9 5 
Total 216 181 203 194 141 145 160 139 160 159 
Other candida species 2 3 0 2 1 1 1 0 2 2 
Candida albicans 0 1 1 1 0 0 3 0 0 1 
Total 2 4 1 3 1 1 4 0 2 3 
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